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The activation of innate immune pathways is a critical step in the response 
to virus infection. The failure of infected cells to control virus replication can lead 
to massive destruction of tissue, resulting in severe illness or death of the host and 
spread to new hosts. The ongoing coronavirus pandemic highlights the critical 
need to understand the mechanisms by which infected cells activate the innate 
immune response following virus infection, and how failure to activate this 
response leads to virus spread and cross-species transmission. Here, I describe 
two model systems used to understand the innate immune response to viruses. 
First, I use genetically engineered reporter influenza A viruses to identify infected 
cells and characterize the early response in vivo. I have found distinct responses 
based on the magnitude and round of infection, as well as cell type- and stage-
specific antiviral signatures. In the second model system, I aim to understand the 
dynamics of how viruses transmit between hosts. I leveraged a model whereby pet 
store mice—which harbor a myriad of mouse pathogens—are co-housed with 
clean laboratory mice. This ‘dirty’ mouse model offers a platform for studying the 
acute transmission of viruses between hosts via natural mechanisms—through 
direct contact, air, and saliva and other fluids. I co-housed pet store mice with wild 
type laboratory mice and mice deficient in interferon receptors to characterize the 
role of these important innate immune pathways. Finally, I have co-housed 
laboratory mice with the bedding of pet store rats to analyze immune and non-
immune species barriers to transmission. Overall, the findings of these studies will 
help elucidate mechanisms of innate immune activation by viruses. 
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Viruses are obligate intracellular parasites that likely infect all forms of life. 
The global virome is incredibly diverse, including diversity in genome 
size/structure, replication cycle, host specificity, and pathogenicity. Advances in 
metagenomics have led to a global estimate of 1031 virus particles in existence at 
any given moment (1). While fewer than 300 viruses are known to infect humans, 
an estimated 600,000-800,000 viruses in mammals or birds have zoonotic 
potential, meaning these viruses do not infect humans but could gain the ability to 
infect humans (2). The most devastating human virus pandemics have occurred 
following emergence from zoonotic reservoirs, including human immunodeficiency 
virus (HIV), Ebolavirus, and avian influenza A viruses (IAVs). The 1918 influenza 
pandemic—which likely emerged from waterfowl (3)—infected over a third of the 
global population and caused 50-100 million deaths. All IAV endemic and 
pandemic strains since 1918 (including the 1957, 1968, and 2009 pandemics) 
have been descendants of the 1918 strain (3), adding millions more deaths 
resulting from a single emergence. The ongoing coronavirus pandemic—which 
was first identified in late 2019 and has over 5,000,000 confirmed cases and nearly 
350,000 confirmed deaths globally (Johns Hopkins University Coronavirus 
Research Center, current as of 22-May-2020)—highlights the need to understand 
mechanisms of emergence. The rapid increase in the global human population 
both increases the occurrence of disease transmission between humans and 
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increases exposure to animal reservoirs. However, it is difficult to identify viruses 
with pandemic potential. Such predictions require both intensive screening of 
animal populations for these viruses and an understanding of the virus and host 
factors that restrict or allow cross-species transmission.  
The innate immune response is a critical line of defense against virus 
infections. Innate immune receptors are antigen non-specific, allowing the host to 
respond to a wide range of pathogens without needing prior exposure. This is 
especially important in the face of emerging viruses for which there is little or no 
existing immunity. While activation of the innate immune response is necessary to 
control virus replication, it can also lead to a robust inflammatory response and 
widespread tissue damage. The failure of infected cells to control virus replication 
can lead to cell death, spread of the virus to neighboring infected cells, 
transmission of the virus to additional hosts, and increased severity of disease or 
death of the host. Understanding the complexities of virus-host interactions at the 
cellular level is important for predicting emerging viruses, developing antivirals to 
contain outbreaks when human infection does occur, and generating effective 
vaccines to prevent pandemics. This introduction will describe the innate immune 
receptors that detect virus infections, the response that is mounted upon receptor 
activation, and highlight how this interaction has driven evolution of both viruses 





INNATE IMMUNE RESPONSE TO VIRUSES 
Detection and response in infected cells 
Detection of viruses by infected cells initiates an immune response to inhibit 
virus replication and protect the host. In mammals, viruses are detected through 
pattern recognition receptors (PRRs), which detect specific viral pathogen-
associated molecular patterns (PAMPs). Virus infections are sensed by 
cytoplasmic sensors such as RIG-I-like receptors (RLRs) and cyclic GMP-AMP 
synthase (cGAS) and membrane-bound toll-like receptors (TLRs). These 
receptors recognize viral nucleic acids: cytosolic double-stranded or uncapped 
RNA (RLRs), cytosolic double-stranded DNA (cGAS), or endosomal nucleic acids 
(TLRs) (4, 5). Upon ligand binding, these receptors signal through their cognate 
adaptor proteins to activate interferon response factor (IRF) -3 and -7. Activated 
IRFs translocate to the nucleus to upregulate, among other genes, type I and III 
interferons (IFNs) (Figure 1-1). The effect of these critical antiviral cytokines will be 
discussed in a later section.  
PRR agonists have been identified using synthetic nucleic acid molecules 
and validated using virus infection models in vitro (6). Aberrant replication 
products—such as defective interfering genomes—are potent RIG-I agonists for 
many RNA virus infections, including IAV (7), Sendai virus (8), and some strains 
of measles virus (9). How and when these agonists are produced is 




Figure 1-1. Detection of viruses upregulates IFN. Viral nucleic acids are detected through 
cytoplasmic RLRs or cGAS (A) or endosomal TLRs (B). This interaction initiates a cascade 
that ultimately leads to phosphorylation of IRF 3 and/or 7 (IRF3/7). Activated IRF3/7 
translocates to the nucleus to upregulate IFN, which is then released from the cell. Image 
created using BioRender.  
 
The interferon response 
The innate immune response induced in infected cells both controls local 
virus replication and has global effects mediated by molecules secreted from 
infected cells, primarily IFN. IFNs act in an autocrine and paracrine manner by 
signaling through the IFN receptors, ultimately upregulating a set of IFN-stimulated 
genes (ISGs) which establish the antiviral state in the host. In addition to IFN, other 
secreted cytokines and chemokines function to induce other aspects of the 
immune response, including inflammation and activation of the adaptive immune 
response.  
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 Type I and type III IFNs (IFN-I and IFN-III) are the primary mediators of the 
antiviral response. These IFNs bind to the IFN-a receptor (IFNaR) and IFN-l 
receptor (IFNlR), respectively, and signal through converging pathways to 
upregulate ISGs (10). Engagement of IFN with its cognate receptor activate Janus 
kinases (JAKs) and tyrosine kinase 2 (TYK2), which then phosphorylate signal 
transducer and activator of transcription -1 (STAT1) or -2 (STAT2). Phosphorylated 
STAT1-STAT2 heterodimers associate with IRF9 to form the heterotrimeric 
complex IFN-stimulated gene factor 3 (ISGF3). This complex translocates to the 
nucleus where it acts as a transcription factor by binding to IFN-stimulated 
response elements (ISRE) to regulate expression of ISGs (Figure 1-2). Semi- or 
unphosphorylated ISGF3 can activate gene expression, both aberrantly and in the 
context of infection (11, 12).  
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Figure 1-2. IFN signaling upregulates ISGs. Binding of IFNs to their congnate receptors 
activates JAKs and TYK2, which phosphorylate STAT1/2. Phosphorylated STAT1/2 
associate with IRF9, and this complex translocates to the nucleus to activate genes 
downstream of ISREs. Image modified from BioRender template.  
 
 While they signal through similar pathways, IFN-I and IFN-III differ in 
important ways. The IFNaR and IFNlR differ in their expression; while the IFNaR 
is expressed on all nucleated cells, IFNlR is restricted primarily to epithelial cells 
(hepatocytes and neutrophils also express IFNlR) (13, 14). Additionally, the 
response to IFN-III is delayed compared to IFN-I (15, 16). Type I IFN-b expression 
is primarily regulated by IRF3, which is constitutively expressed and activated upon 
virus infection. In contrast, type III IFNs require IRF7, an ISG, which may explain 
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the delayed IFN-III response (13). However, rapid and robust induction of IFN-III 
has been observed under certain conditions in vitro and in vivo (17, 18).  
IFN-I has long been considered the primary inducer of an effective antiviral 
response. However, in epithelial tissues such as the lung and gut, IFN-III has a 
nonredundant role in controlling virus infections. IFN-III signaling has been shown 
to be sufficient for protecting mice against IAV infection in the absence of IFN-I 
signaling (18). This is also true in intestinal infections; IFN-III signaling is necessary 
for norovirus clearance independent of adaptive immunity (19). Additionally, the 
IFN-III response is less inflammatory than IFN-I due to their differential ability to 
upregulate IRF1 (16, 20). Mice deficient in IFN-III signaling have higher IAV loads 
and more lung damage compared to IFN-I deficient mice. Moreover, a lack of IFN-
III production resulted in enhanced IFN-I production, more robust innate immune 
cell infiltration, more extensive tissue damage, and ultimately increased mortality 
(21), suggesting that IFN-III is more important for host survival during IAV infection.  
 
IFN-stimulated genes 
 ISGs are broadly defined as genes upregulated following IFN stimulation of 
cells. In a single cell, hundreds of genes are induced by IFN, and an estimated 
10% of the human genome has the potential to be regulated by IFN (22). However, 
while screens using different species and cell types have identified many ISGs, 
when compared across animals only 62 genes were found to be commonly 
upregulated following IFN-I stimulation (22). This suggests that there are a set of 
conserved ISGs, but also species-specific ISGs. Many ISGs have unknown 
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antiviral functions and, despite robust protection following IFN treatment, few ISGs 
display antiviral activity when expressed individually in cells (23, 24). IFN treatment 
still effectively protects against virus infections in vitro, which could suggest that 
ISGs work cooperatively through unknown mechanisms to inhibit virus replication.  
ISGs exert their effects both directly and indirectly. For example, 
components of the RIG-I pathway—including Ddx58 (RIG-I), Mavs, and Irf3/7—
are ISGs and promote an antiviral state without directly interfering with the virus 
life cycle. Directly antiviral ISGs have been found to target many stages of virus 
infection. ISGs inhibit IAV entry (IFITM3) (25, 26) replication (PKR) (27), and 
egress (SERPINE1) (28). Some ISGs have been identified to have proviral 
functions. For example, LY6E promotes entry of a subset of RNA viruses, including 
Dengue virus and IAV (29). The endosomal cation channel MCOLN2 enhances 
infection of several viruses by promoting intracellular trafficking of endocytosed 
virions (30). Other putative proviral ISGs have been identified (including ADAR, 
FAM46C, and APOBEC3A) (23), but their mechanisms remain undefined.  
While they are defined by their IFN responsiveness, some ISGs can be 
upregulated directly by virus infection independent of IFN signaling. Herpesvirus 
infection—including human cytomegalovirus and herpes simplex virus-1—can 
upregulate ISGs through IRF3 and STAT1 activation (31). Similarly, vesicular 
stomatitis virus and IAV upregulate IRF1 and IRF3, respectively, to upregulate 
ISGs independent of IFN (32, 33). Activation of IRF3/7—and subsequent 
upregulation of antiviral genes—has been documented following virus entry 
independent of PRR signaling and IFN (34, 35). These data suggest direct 
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induction of ISGs as a mechanism to rapidly establish the antiviral state during 
infection.  
 
Inflammation, cell death, and activation of the adaptive immune response 
Activation of PRRs and signaling through IFN receptors also upregulates 
classes of cytokines and chemokines that initiate and regulate the inflammatory 
response. While inflammation is critical to clearing infection, it also contributes to 
tissue destruction and severity of disease. Expression of pro-inflammatory 
cytokines is primarily mediated by the transcription factor nuclear factor k-light-
chain-enhancer of activated B cells (NFkB), which is activated by PRR signaling 
along with IRF3/7. Many factors contribute to the balance between IRF and NFkB 
activation, including age of the host (36) and expression of the scaffold protein 
CARMA3, which positively regulates MAVS-mediated NFkB activation (37). 
Additional uncharacterized viral and host factors may contribute to balancing 
between the antiviral and inflammatory functions of PRR and IFN responses. 
Death of infected cells through apoptosis is a mechanism to inhibit virus 
replication by removing access to necessary host factors. Virus infection can 
induce cell death through both intrinsic pathways (e.g. through DNA damage or 
metabolic stress) and extrinsic pathways through the release of cytokines and 
activation of death receptors (38). Many viruses express proteins that induce or 
suppress apoptosis, suggesting apoptosis is both a pro- and antiviral process, 
depending on the biological context. Herpesviruses and poxviruses, among others, 
express proteins homologous to host antiapoptotic proteins as a way to inhibit 
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apoptosis and favor virus propagation (38). In contrast, norovirus and other 
Calicivirus species express polyproteins that are cleaved by host caspases at late 
timepoints (18-24h post-infection), and these cleaved proteins further promote 
caspase activity and cell death, leading to spread of new viruses to neighboring 
cells (39, 40), suggesting apoptosis as a proviral mechanism. Whether pro- or anti-
viral, widespread apoptosis has a profound impact on the pathogenesis of viral 
infections. IAV both directly induces apoptosis in infected cells and indirectly 
through inflammatory and cytotoxic T cell responses (41). In mice, an inability to 
control IAV infection through IFN-I induction led to a robust inflammatory response 
and inflammasome-induced lethality (36). However, in some strains of mice, the 
IFN-I response leads to uncontrolled inflammation, extensive lung damage, and 
ultimately increased mortality (42). Altogether, apoptosis and inflammation must 
be tightly regulated to balance between virus clearance and tissue damage.   
Both inflammatory signals and cell death-associated signals recruit and 
activate innate immune cells, including macrophages and dendritic cells (43-45). 
Innate immune cells serve as the bridge between the innate and adaptive immune 
response. These cells acquire viral antigens—either through direct infection or 
phagocytosis—and present these antigens to activate naïve T and B cells to 
establish long-lasting immunity to specific viral pathogens. RIG-I signaling in 
dendritic cells and other hematopoietic cells is critical for generating functional 
memory T cells (46), and IFN-III signaling promotes generation of antibodies (47) 
during IAV infection, further highlighting the importance of an effective innate 
response in protecting the host from ongoing and future infections.  
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Negative regulation of the innate immune response 
 While innate immune control of virus replication promotes survival of the 
host, the response must also be tightly regulated to prevent widespread tissue 
damage due to inflammation, cytotoxic immune cells, and virus-induced apoptosis. 
Key signaling proteins are often only transiently turned on, and many ISGs serve 
as inhibitors of PRR or IFN signaling. Binding of IFN-I to the cognate receptor leads 
to endocytosis of the receptor-ligand complex and degradation of the receptor (48-
51). IRF and STAT proteins are regulated via post-translational modifications such 
as phosphorylation, ubiquitination, and acetylation; the addition and removal of 
these modifications can happen rapidly, allowing for control of signaling without 
changing expression of these genes (52, 53). PRR and IFN signaling also 
upregulate negative regulators of the response. Two ISGs are major negative 
regulators of IFN: USP18 and suppressor of cytokine signaling (SOCS) proteins. 
SOCS proteins bind to both the IFNAR and JAK proteins to prevent interaction with 
STATs (54, 55). SOCS1 can also attenuate IFN-III signaling (56). USP18 binds to 
IFNaR to prevent JAK binding and subsequent signaling (57). In contrast to 
SOCS1, USP18 only regulates IFN-I (56). Negative regulation of RIG-I and MDA5 
by an additional RLR, LGP2, has been documented, however LGP2 has also been 






Non-canonical innate immunity  
Innate immune receptors and effectors are defined by their consistent 
response regardless of previous exposure to a given pathogen, which is in contrast 
to the memory associated with adaptive immunity. The activation of these 
pathways has been viewed as similarly consistent, with different cell types able to 
respond to a wide range of pathogens in a similar manner. There are several 
important exceptions to this rule, and recent findings have also shifted away from 
the idea that innate immunity is absent of memory.   
Many recent studies using single-cell RNA sequencing or other deep 
sequencing techniques have identified both heterogeneous virus replication 
between infected cells and heterogeneous responses from infected cells. This has 
been documented for IAV (62, 63), West Nile virus (64), herpes simplex virus-1 
(65), and foot-and-mouth disease virus (66), among others. These studies have 
identified both virus and host factors that contribute to the observed heterogeneity, 
and these factors also contribute to a heterogenous innate immune response. For 
example, cells infected with an IAV virion lacking a polymerase gene contain lower 
amounts of virus RNA, and cells infected with a virion lacking the immune 
antagonist nonstructural 1 (NS1) gene produce more IFN (63). The level of foot-
and-mouth disease virus replication varies with host cell cycle phase (66). Many 
of these studies have been completed in in vitro systems. Similar heterogeneity in 
both the virus and response likely exists in vivo, and there are likely many unknown 
contributing factors.  
 13 
 Cell type-specific responses to both infection and IFN have been well 
described. Hematopoietic cells—particularly monocytes—have higher basal and 
induced IFN-I responses than non-hematopoietic cells (67). Stem cells display a 
unique resistance to many viral infections (68-71). For decades, the mechanism of 
this resistance was unknown. Recently, it was found that pluripotent and 
multipotent cells basally express canonical ISGs (72). This finding is consistent 
across different types of stem cells, and the intrinsic expression of ISGs is critical 
in mediating resistance to infection. Stem cells also do not produce nor respond to 
IFN-I (73, 74). Induced activation of IRF7 in induced pluripotent stem cells resulted 
in both short- and long-term transcriptional changes that reduced the differentiation 
potential of these cells (74). This suggests that the IFN resistance of stem cells 
preserves their pluripotency, and the intrinsic expression of ISGs is critical for them 
to survive viral infections. Viruses require many host factors for replication—
discussed in a later section—and different cell types may express such factors at 
different levels. Therefore, additional cell type-specific responses likely exist but 
have yet to be characterized.  
Several recent studies have documented innate immune ‘memory,’ or the 
ability of cells to respond more rapidly to stimuli after a prior exposure. Innate 
immune memory is mediated by epigenetic changes that make cells more 
responsive to secondary stimuli. Macrophages can be ‘trained’ by priming with b-
glucan, which alters the histone acetylation profile of several promoters to make 
them more responsive to subsequent infection (75). In both hematopoietic and 
non-hematopoietic cells, ISGs accumulate the activation-associated histone H3.3 
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as they are transcribed. This confers ‘transcriptional memory’ that permits faster 




Non-immune host responses to virus infection 
 Beyond activating immune pathways, viruses have an extensive impact on 
the host cell. Viruses require host machinery for replication, transcription, 
translation, entry/egress, and trafficking through the cells. siRNA screens have 
identified hundreds of host proteins required for IAV protein localization, genome 
transcription and replication, and virus packaging and budding (79, 80). In addition 
to using host proteins directly, viruses need access to host metabolites, including 
nucleotides and amino acids, and therefore can have a profound impact on host 
cell metabolism. Many viruses shift the balance between glycolysis and oxidative 
phosphorylation in infected cells, and this shift can go either direction depending 
on the requirements for the virus. Certain strains of rubella virus induce oxidative 
phosphorylation to provide glutamine to promote virus replication (81). In contrast, 
Dengue virus induces glycolysis (82). The requirement of non-immune proteins for 
virus replication adds complexity to virus-host interactions, and—along with innate 





The molecular arms race between virus and host 
The host immune response places enormous evolutionary pressure on 
viruses. Many viruses encode proteins that antagonize innate immune signaling or 
directly inhibit antiviral proteins. The primary immune antagonist protein for IAV—
NS1—has been found in both the nucleus and cytoplasm of infected cells, where 
it completes diverse antiviral mechanisms. NS1 proteins of various IAV strains 
have been found to inhibit RIG-I directly, inhibit IFN-I production, directly inhibit the 
antiviral proteins PKR and 2’-5’ oligoadenylate synthetase (OAS), and interfere 
with various other host processes to promote virus propagation (83). Both IAV NS1 
and the recently identified polymerase acidic-X (PA-X) also regulate host shutoff, 
or the inhibition of host gene expression as both a mechanism to prevent antiviral 
gene expression and to promote viral gene expression (84, 85). HIV-1 viral 
infectivity factor (Vif) is also a multifunctional protein, but the best-characterized 
function is inhibiting host APOBEC3 proteins, a family of DNA cytosine 
deaminases that restrict HIV-1 by driving deleterious hypermutation in the viral 
cDNA (86). Vif coordinates an E3 ubiquitin ligase complex that results in the 
degradation of several host APOBEC proteins. A recent study also suggests Vif 
induces cell cycle arrest to promote virus replication through an unknown 
mechanism (87). Many virus-encoded proteases—including those of hepatitis C 
and hepatitis A viruses—cleave MAVS to inhibit PRR signaling (88). These are just 
three well-characterized examples of viral immune antagonists, but the overall 
prevalence of such proteins in the global virome suggests the innate immune 
response is a prominent driver of virus evolution. 
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Viruses also exert an immense amount of selective pressure on hosts. As 
viruses evolve to evade host defenses, the host must also adapt to continue to 
combat virus infections. This creates a molecular arms race between virus and 
host, leading to the adaptation and evolution of both viral and host species. 50,000-
100,000 years ago, modern humans and Neanderthals co-existed and interbred. 
After thousands of years of recombination and purifying selection, remnants of 
Neanderthal genes still exist in the human genome; approximately 2-3% of the 
genome in Asian and European humans is of Neanderthal origin. These 
introgressed gene segments are strongly enriched for virus-interacting proteins 
(89). Moreover, computational analyses comparing virus interacting proteins to the 
entire human proteome revealed that viruses drive approximately 30% of all 
protein adaptations (90). These data implicate viruses as the dominant driver of 
protein adaptations in humans and other mammals.  
Many antiviral mechanisms target and disrupt virus gene expression by 
inhibiting replication or preventing translation of virus mRNA. This introduces the 
critical need to distinguish between virus and host; aberrant targeting of host genes 
can ultimately harm rather than protect the host. The host therefore has to balance 
evolution of antiviral defenses with maintenance of fitness. For example, antiviral 
OAS proteins sense double-stranded RNA and activate RNase L to cleave the 
RNA (91). However, due to the limited binding preference for nucleotide 
sequences and resulting targeting of host RNAs, OAS1 is lost in many primate 
species (92, 93). Viruses—due to their restricted genetic space—must also 
balance antiviral antagonism with fitness. Certain adaptations in IAV nucleoprotein 
 17 
(NP) confer resistance to the host antiviral factor MxA (94, 95). However, these 
adaptations also destabilize NP and create a requirement of heat shock-regulated 
host chaperones for IAV propagation (96). Under restrictive temperatures (i.e. in 
the absence of heat shock), NP either adapts immune evasion and becomes 
unstable or retains stability but is susceptible to MxA-mediated restriction.  
Many RNA viruses lack proofreading functions and therefore accrue many 
more mutations during their life cycle compared to hosts. This difference in 
mutation rates between virus and host—RNA viruses have mutation rates up to a 
million times higher than their hosts (97)—and the need to defend against many 
pathogens presents an interesting problem: how can the host possibly keep up? 
Many—if not all—virus antagonist proteins are under positive selection, meaning 
they have an accelerated accumulation of coding mutations, particularly in regions 
that directly interact with viral products (88). Another common mechanism of 
antiviral evolution is gene duplication. This gives the host genetic space to evolve 
to escape virus antagonism or gain resistance to new viruses without sacrificing 
established antiviral functions. This mechanism has been documented for many 
antiviral gene families, including IFIT (98) and APOBEC3 (86, 99). The 
antiretroviral TRIM5-cyclophilin A (CypA) fusion protein has evolved independently 
in two distinct lineages via retrotransposition. This fusion swaps the retrovirus 
capsid recognition domain of TRIM5 for that of CypA, creating a protein with novel 
antiretroviral recognition and inhibition (100). As the host continues to evolve, the 
pressure is placed back on the virus to evade the immune response. Continued 
research into the ongoing arms race between viruses and host will reveal 
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additional host adaptation strategies. The identification of novel viruses in 
mammals and emergence of novel viruses into the human population will also 
reveal new host immune mechanisms and virus immune antagonists.   
 
CONCLUSIONS 
 Emerging viruses remain a significant threat to public health. In this chapter, 
I have highlighted the role of the innate immune response in controlling virus 
replication and spread in a host, and how the relationship between virus and host 
has shaped evolution in both species. Several important questions remain, 
including virus and host factors that drive effective immune responses in vivo and 
what virus and host factors contribute to cross-species transmission. These 
questions will be addressed in subsequent chapters of this thesis.  
In Chapter 2, I will discuss the heterogeneity in IAV replication during the 
early days of infection in vivo. We hypothesized that this heterogeneity would 
correlate with differences in the antiviral response in infected cells. We also 
hypothesized that the immune response initiated by the first infected cells would 
affect tropism of IAV as it spreads within the lung in vivo.  
 Chapter 3 will characterize an additional reporter IAV that allows dissection 
of the immune response to primary IAV mRNA transcription and subsequent 
replication of genomic viral RNA. We hypothesized that there would be distinct 
responses to these two stages of IAV replication in vivo. This study also 
interrogates the epithelial cell type-specific responses to infection. Lung epithelial 
cell subsets have distinct functions under homeostatic conditions, and we therefore 
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hypothesized that different cell types would have distinct antiviral responses in 
vivo.   
 Chapter 4 will introduce a new model to analyze intra- and inter-species 
transmission of viruses and other pathogens. In this model, pet store mice 
harboring myriad pathogens are co-housed with our specific pathogen-free 
laboratory mice, resulting in transmission of pathogens via natural transmission 
routes. We use both wild type and IFN receptor knockout mice, allowing us to 
assess the role of the IFN response in controlling virus transmission to and 
dissemination within a host. This model uniquely allows access to both the 
reservoir and host, giving the opportunity to identify virus mutations and 
adaptations that occur during transmission and dissemination. Using pet store rats, 
we have also expanded this model to interrogate species barriers to transmission.  
 The data presented in Chapters 2 and 3 offer new insight into IAV and host 
factors that affect innate immune activation and regulation of the response. The 
model in Chapter 4 has significant potential to interrogate the role of the innate 
immune response in intra- and inter-species transmission. In Chapter 5 will 
highlight how these recent findings have deepened our understanding of the innate 




1Abbreviations used this chapter: AMP, adenosine monophosphate; APOBEC, 
apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like; CARMA3, 
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caspase recruitment domain and membrane-associated guanylate kinase-like 
protein 3; cGAS, cyclic GMP-AMP synthase; CypA, cyclophilin A; GMP, guanosine 
monophosphate; HIV, human immunodeficiency virus; IAV, influenza A virus; 
IFITM3, IFN-induced transmembrane protein 3; IFN, interferon; IFNaR, IFN-a 
receptor; IFNlR, IFN-l receptor; IRF, IFN response factor; ISG, IFN-stimulated 
gene; ISGF3, IFN-stimulated gene factor 3; ISRE, IFN-stimulated response 
element; JAK, Janus kinase; LGP2, laboratory of genetics and physiology 2; LY6E, 
lymphocyte antigen 6 family member E; MAVS, mitochondrial antiviral signaling 
protein; MCOLN2, mucolipin-2; MDA5, melanoma differentiation-associated 
protein 5; mRNA, messenger RNA; NFkB, nuclear factor k-light-chain-enhancer of 
activated B cells; NP, nucleoprotein; NS1, nonstructural 1; OAS, oligoadenylate 
synthetase; PA-X, polymerase acidic X; PAMP, pathogen associated molecular 
pattern; PKR, protein kinase R; PRR, pattern recognition receptor; RIG-I, retinoic 
acid inducible gene 1; RLR, RIG-I-like receptor; siRNA, small interfering RNA; 
SOCS, suppressor of cytokine signaling; STAT, signal transducer and activator of 
transcription; TLR, toll-like receptor; TRIM5, tripartite motif containing 5; TYK2, 







CHAPTER 2: Distinct antiviral signatures revealed by the magnitude and 
round of influenza virus replication in vivo 
 
SUMMARY 
Influenza virus has a broad cellular tropism in the respiratory tract. Infected 
epithelial cells sense the infection and initiate an antiviral response. To define the 
antiviral response at the earliest stages of infection we used a series of single cycle 
reporter viruses. These viral probes demonstrated cells in vivo harbor a range in 
magnitude of virus replication. Transcriptional profiling of cells supporting different 
levels of replication revealed tiers of interferon-stimulated gene expression. 
Uninfected cells and cells with blunted replication expressed a distinct and 
potentially protective antiviral signature, while cells with high replication expressed 
a unique reserve set of antiviral genes. Finally, we used these single cycle reporter 
viruses to determine the antiviral landscape during virus spread, which unveiled 
disparate protection of epithelial cell subsets mediated by interferon in vivo. 
Together these results highlight the complexity of virus-host interactions within the 




Influenza A virus (IAV) drives significant morbidity and mortality worldwide 
each year. IAV has a broad cellular tropism in the respiratory tract with the ability 
to infect many epithelial cell types (101). Rig-I-like receptors detect virus in 
epithelial cells, resulting in the production of type I and III interferons (IFNs) and 
other proinflammatory cytokines (10). IFNs act through autocrine and paracrine 
signaling pathways to induce the production of IFN-stimulated genes (ISGs), which 
promote a general antiviral state. Several individual ISGs have been identified that 
perturb IAV at multiple stages of the viral life cycle. For example, IFITM3 blocks 
entry, Mx disrupts the IAV polymerase, and PKR inhibits viral protein synthesis 
(27, 102-105). The induction of an antiviral state can also be driven directly by virus 
replication, independent of IFN signaling (32, 106, 107). It is unknown how the 
level of virus replication within a single cell affects the induction of global cellular 
responses. Even in the presence of a robust antiviral response, some infected cells 
continue manufacturing new viruses and naïve cells still become infected. How the 
antiviral response alters tropism during virus spread has not been determined. 
Studies aimed at determining the cellular response to IAV infection have 
been performed by exploiting powerful genetic systems (CRISPR, RNAi, yeast 
two-hybrid, etc.) in vitro or by assessing bulk infected tissue in vivo (105, 108-110). 
While these analyses have been critical for evaluating host factors that support or 
inhibit IAV, the understanding of the complex interplay between different cell types, 
anatomical locations, and immune responses in the context of virus infection in 
vivo is still incomplete. Single cell analyses can help bridge this gap and have 
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demonstrated the heterogeneity in IAV replication and the antiviral response in 
vitro (62, 111, 112). Unfortunately, current single cell mRNA-seq strategies using 
wt virus cannot distinguish between newly infected cells and cells in which 
replication has been controlled in vivo.  
To overcome these limitations, we engineered a reporter virus to specifically 
label cells in the first round of replication. This virus cannot spread; therefore, any 
differences in viral abundance will be a direct result of replication intensity. 
Infection of mice revealed uninfected cells and cells with both low and high levels 
of virus replication. These populations exhibited unique ISG signatures, and this 
finding was corroborated through the use of a reporter virus capable of specifically 
detecting active replication. This suggests that the antiviral response is tuned to 
the level of virus replication to generate a response appropriate to the level of 
threat. To understand how the antiviral response and tropism change from the first 
to second wave of replication we sequentially infected mice with viruses incapable 
of spreading. This strategy uncovered differential protection of ciliated epithelial 
cells mediated by IFN. These data demonstrate that epithelial cells supporting high 
or low levels of replication in vivo display tailored antiviral responses and that 
protection afforded by IFN is not equal amongst all cell types during virus spread. 
Together these findings demonstrate the complexity of virus-host interactions in 





MATERIALS AND METHODS 
Mice and virus infection  
C57BL/6J mice were purchased from The Jackson Laboratory. Mice were 
infected intranasally (i.n.) with the indicated doses of scIAV. Inactivated virus was 
generated through 20 minutes of UV exposure at room temperature. Carrier-free 
IFNb1 (1.5-3 µg/mouse) and l3 (2.5-3 µg/mouse) (R&D Systems) were 
administered i.n.. BrdU was administered i.p. at 1 mg/mL prior to infection and 
supplemented in the water at 0.8 mg/mL. Experiments involving mice were 




Madin-Darby Canine Kidney (MDCK) cells expressing WSN HA (MDCK 
WSN HA, kind gift from Dr. Adolfo García-Sastre, Mount Sinai), MDCK expressing 
PR8 HA (MDCK PR8 HA, kind gift from Dr. Luis Martinez-Sobrido, University of 
Rochester), and HEK293T cells (293T, ATCC) were maintained in DMEM with 
10% FBS and 1% penicillin/streptomycin. MDCK PR8 HA cells were supplemented 
with 0.25 mg/mL hygromycin B.  
 
Virus Rescue  
Viruses were rescued in 293T cells by plasmid-based transfection with IAV 
PR8 in the pDZ vector using methods previously described (113, 114). The 5’ (106 
bp) and 3’ (156 bp) packaging signals were preserved, except AUG codons in the 
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5’ packaging signal were mutated. The designed gene of interest (mCherry, GFP, 
destGFP (pCAG-GFPd2 was a gift from Connie Cepko, Addgene plasmid #14760 
(115)), or Cre recombinase) was cloned in between the HA packaging signals. 
pCAGGs WSN HA plasmid was supplemented into the transfection. 24 h following 
transfection, 750,000 MDCK WSN HA cells were added to the culture in Opti-MEM 
containing TPCK trypsin (0.5µg/mL). The following day, 500 µL Opti-MEM 
containing TPCK trypsin (1 µg/mL) was added. The next day, 500 µL Opti-MEM 
containing TPCK trypsin (2 µg/mL) was added to the culture. One day later, the 
supernatant was harvested, centrifuged to remove cellular debris, and stored at -
80°C. Viruses were then grown on MDCK PR8 HA cells to exchange the HA from 
WSN to PR8. Plaque assays were carried out in MDCK WSN HA cells. Infections 
were carried out in infection media (PBS with 10% Ca/Mg, 1% pen/strep, 5% BSA) 
at 37°C for 1 h. Infection media was then replaced with an agar overlay (MEM, 
1mg/mL TPCK trypsin, 1% DEAE-dextran, 5% NaCO3, 2% agar) and cells cultured 
at 37°C for 40 h and then fixed with 4% formaldehyde. Blocking and 
immunostaining were done for 1 h at 25°C in 5% milk using the following 
antibodies: polyclonal anti-IAV PR8/34, 1:5000 (V301-511-552), Peroxidase 
Rabbit Anti-Chicken IgG, 1:5000 (303-035-003, Jackson Immuno Research). 
TrueBlue Peroxidase Substrate (50-647-28, Kirkegard & Perry Laboratories) was 






Mice were euthanized and lungs were inflated with 2 mL dispase (Corning) 
and 0.5 mL 1% low melt agarose (Lonza) and allowed to sit covered with an ice 
pack for two minutes. Lungs were then removed from mouse and transferred to 1 
mL dispase and incubated at room temperature for 45 minutes. Next, lungs were 
cut into pieces and transferred to DMEM with DNase I (Sigma-Aldrich) 95 U/mL 
and shaken for 10 minutes at room temperature. Solution was filtered off and lungs 
were homogenized in GentleMACS dissociator in harvest buffer (RPMI1640 with 
4% bovine serum, 1% HEPES, and 1% L-glutamine). Red blood cells were lysed 
with ACK buffer and cells were filtered through 70 µm filter mesh to obtain a single 
cell suspension prior to staining. Cells were stained with Ghost Dye Red 780 
(Tonbo), followed by the following antibodies against surface markers: CD45 (30-
F11), Podoplanin (clone 8.1.1), CD24 (M1/69) (Biolegend), CD31 (clone 390, BD 
Bioscience). Prior to intracellular BrdU staining, cells were fixed overnight using 
the BD CytoFix/Cytoperm kit (BD Biosciences) and treated with DNAse I (2.5 
mg/mL, Sigma-Aldrich). Fixed cells were stained for intracellular BrdU (clone 
MoBU-1, Life Technologies). Cell counts were obtained using AccuCheck counting 
beads (Thermofisher Scientific). Data was acquired on a BD LSRFortessa (Becton 






Next-generation mRNA sequencing analysis 
Mice were infected and lung epithelial cells were FACS sorted as stated 
previously. Cells were sorted into 1.5 mL microcentrifuge tube and RNA was 
isolated using RNeasy Micro or Micro Plus kit (Qiagen) The cDNA library was 
prepared using the SMARTer Universal Low Input RNA Kit (Takara Bio). Samples 
were sequenced as 50 base pair single-end reads using the HiSeq2500. We 
obtained an average of 12 million reads per sample. Sequencing reads were 
mapped to the mouse (mm10) and influenza A/PR/8/34(H1N1) genomes using 
Bowtie aligner (bowtie2 version 2.2.4) with local mode, 22 nt seed sequence, and 
≤1 nt mismatch (-L 22 and -N 1 parameters) (116). Reads were subsequently 
sorted and filtered by removing the PCR duplicates with Samtools (version 1.16) 
(117) and were assigned to Ensembl gene model 
(Mus_musculus.GRCm38.87.gtf) with featureCounts of the Subread software 
package (version 1.5) (118). For the IAV read assignment, reads were mapped to 
the combined mm10 and IAV mRNA (Influenza Research Database). Both reads 
assignment tables were merged to create raw reads count matrix for subsequent 
statistical analysis. To determine if IAV transcripts were truncated in some 
samples, sample raw reads that were mapped to the customized reference (mouse 
genome and IAV mRNA) were visualized in the Integrated Genome Viewer (IGV) 
(119). Scales were adjusted to make coverage profiles more easily comparable 
across samples. The 221 differentially expressed ISGs in either mCherry low or 
high group were selected for further cluster analysis (FDR < 0.05). The default 
scaling and hclust method in complex heatmap package was used for clustering 
 28 
and generating heatmap (120). The same cutoff was applied to destabilized GFP 
experimental groups and 197 ISGs were selected for cluster analysis as described 
above. To obtain significant differentially expressed genes, the experimental 
groups by design were compared to control group (naïve or negative) and the 
edgeR bioconductor package was used for statistical analysis (121, 122). 
Sequencing data deposited under GEO series accession number GSE112794.  
 
Microscopy and histo-cytometry 
Lungs were fixed for 2h in 2% paraformaldehyde and inflated before being 
flash frozen in optimum cutting temperature compound. Sections were cut with a 
Leica CM1860 cryostat and stained before imaging with a Leica DM6000B EPI 
fluorescent microscope (violet LED). The following antibodies were used: primary 
antibodies: α-CC10 (polyclonal, Abcam) and α-proSP-C (polyclonal, Millipore 
Sigma); secondary antibody: goat α-rabbit (polyclonal, ThermoFisher). Histo-
cytometry analysis was performed with Imaris (Bitplane) by gating the low and high 
mCherry cells according to mean fluorescence intensity (MFI) using scIAV-ctrl to 
determine background levels of mCherry fluorescence. An additional gate was 








Statistical analysis was executed using GraphPad Prism 7 software. 
Comparisons between two groups were performed using a two-tailed Student t 
test, and p<0.05 was considered statistically significant. Error bars are calculated 
using standard error of the mean. 
 
RESULTS 
Single-cycle infection reveals IAV replication heterogeneity in vivo 
To determine the infected cell landscape during the first round of IAV 
replication in vivo we engineered a reporter virus incapable of disseminating. The 
Hemagglutinin (HA) open reading frame of IAV was replaced by mCherry while 
preserving complete HA vRNA 3’ and 5’ packaging signals and virus grown in an 
HA complementing cell line (123, 124). The virus cannot produce de novo HA 
protein and assemble new virions that can infect other cells (thus termed single-
cycle IAV (scIAV)). Infection of mice revealed three distinct populations of lung 
epithelial cells: those with no, low, or high mCherry fluorescence (Figure 2-1A). 
The heterogeneity in mCherry expression suggests that virus polymerase activity 
during the early stages of scIAV infection varies from cell to cell. Both low and high 
mCherry populations were observed at similar ratios at both 12 and 24 hpi (Figure 
2-1A) and required de novo virus polymerase activity (Figure 2-2A and B). Both 
mCherry low and high CD24high and podoplanin+ (pdpn) (ciliated epithelial cells and 
type I alveolar (ATI) cells, respectively) were identified, suggesting cell type does 
not drive replication heterogeneity (Figure 2-2C).  
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Replication disparity could be driven by anatomical location and/or proximity 
to other infected cells. To address this, mice were infected with scIAV-mCherry 
and lungs were analyzed by fluorescence microscopy. We detected mCherry low 
and high cells in both large and small airways and did not observe any restriction 
based on proximity to other infected cells (Figure 2-1B and 2-2D). To further define 
tropism during the first round of infection, we determined the number of mCherry 
low and high club cells (CC10) and type II alveolar cells (SPC). We found similar 
ratios of mCherry low to high cells in both cell types (Figure 2-2E-H), suggesting 
that heterogeneity in early virus replication levels is not driven by cell type. 
Multiple IAV particles can infect a single cell, which could drive differences 
in fluorescence intensity between cells. To address this, mice were infected with a 
mixture of scIAV-mCherry and scIAV-GFP. At 24 hpi there was only a small 
percentage of mCherry-GFP double positive cells. (Figure 2-1C). The difference in 
fluorescence intensity between the low and high populations is approximately 25-
fold (Figure 2-2I), further suggesting that infection with multiple particles is not 
driving the disparity. To determine if the range of replication is dependent on virus 
dose, mice were infected with a 10-fold lower inoculum of scIAV-mCherry and cells 
supporting low and high replication were still observed (Figure 2-2J). 
Prolonged presence of infectious particles in the lungs could result in varied 
time of infection and lead to replication disparity. This is unlikely given the speed 
of IAV entry in vitro and that virus dose and duration of infection did not impact 
heterogeneity in single cell analyses (62, 125, 126). However, the half-life of an 
infectious particle in vivo has never been experimentally determined. We exploited 
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the scIAV system to address this question. Because scIAVs cannot spread, only 
viruses that have not yet entered a cell can be detected by plaque assay. Mice 
were infected with scIAV-mCherry and virus titer from the lungs determined at 6, 
12, and 24 hpi. By 6 hpi, only ~6% of the virions delivered in the initial dose were 
detectable in the extracellular lung environment with a half-life of ~1.7 h (Figure 2-
1D). This is consistent with mathematical modeling experiments, which predicted 
a half-life between 0.6 and 3 h (127, 128). Therefore, the vast majority of virions 






Figure 2-1. Heterogeneity in replication levels of IAV in epithelial cells in vivo. (A) Mice 
were infected with 105 pfu of scIAV-ctrl (left) or scIAV-mCherry and live, CD45-CD31- cells 
analyzed for mCherry expression at 12 (middle) or 24 (right) hpi. Data are representative 
of 2 (12 hpi) or 10 (24 hpi) experiments with 3-4 mice per group. (B) Naïve mice (left) or 
mice infected with scIAV-mCherry (middle, right) and analyzed for mCherry low and high 
cells by histo-cytometry. Images are representative of 2-3 experiments with three mice per 
group and 2 sections per lung. (C) Mice were co-infected with 105 pfu of scIAV-mCherry 
and 105 pfu of scIAV-GFP. Live, CD45-CD31- cells analyzed for GFP and mCherry 
expression 24 hpi (left). Total mCherry+, mCherry-high, mCherry-low, and GFP+mCherry+ 
cells were quantified (right). Data representative of 3 experiments with n=3-4 mice per 
group. (D) Mice were infected with 105 pfu of scIAV-mCherry and virus from lungs titered 











Figure 2-2. Heterogeneity in replication levels of IAV in epithelial cells in vivo. (A) Ratio of 
mCherry high to low cells determined by flow cytometry. (B) Mice infected with scIAV-
mCherry or UV killed scIAV-mCherry and CD45-CD31-cells analyzed at 24 hpi Y-axis side 
scatter (SSC). (C) Frequency of podoplanin+ (left) or CD24high (right) cells among the 
CD45-CD31- mCherry negative, low, and high populations. Data representative of 5 
independent experiments with 3-4 mice per group. (D) Mice infected with scIAV-mCherry 
and MFI of mCherry+ lungs cells analyzed by histo-cytometry. (E and F) Mice infected with 
scIAV-mCherry and lungs analyzed for CC10 (E) and SPC (F). Arrows indicate cells 
double positive for mCherry and either CC10 or SPC. Red arrows-mCherry high cells. 
Yellow arrows-mCherry low cells. Scale bar = 100µ . Images are representative of 1-2 
independent experiments with 3 mice per group and 2 sections per lung. (G) Frequency 
of CC10+ or SPC+ cells among the mCherry+ population. (H) Ratio of mCherry high and 
low cells in total, CC10+ and SPC+ cells. (I) gMFI of mCherry of mCherry+CD45-CD31- 
cells by flow cytometry. (J) Mice were infected with 104 pfu of scIAV-mCherry and CD45-
CD31- cells analyzed for mCherry expression at 24 hpi Y-axis side scatter (SSC). 
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High levels of replication reveal a distinct antiviral gene signature 
To investigate the intracellular responses to variable levels of IAV 
replication we profiled the transcriptomes of CD45-CD31- mCherry negative, low, 
and high cells by mRNA-seq. Reads that mapped to the IAV genome were 
markedly higher in the mCherry high population compared to low or negative 
(Figure 2-3A), validating the use of mCherry expression level as a surrogate for 
virus replication. Failure to package or express all eight segments or internal 
truncations of segments can result in attenuated replication (129-131). Normalized 
read counts between segments were similar between mCherry low and high cells 
and read abundances across segments did not reveal differences in internal 
truncations between infected cell populations (Figure 2-4A and B) suggesting that 
we are detecting bona fide infected cells. Multidimensional scaling (MDS) of mouse 
transcripts demonstrated significant differences between mCherry low and high 
cells across the first two dimensions (Figure 2-3B). Importantly, the negative 
population was derived from the same lung as mCherry+ cells and was subjected 
to the same inflammatory environment, making it an effective control for 
determining virus replication-specific gene signatures. Global changes in the 
transcriptional response of mCherry low and high compared to mCherry negative 
were analyzed by gene ontology (GO) enrichment. mCherry low and high cells 
downregulated many of the same pathways, primarily those involved in cell 
adhesion, extracellular matrix, and development (Figure 2-4C). Cell death 
pathways were increased in mCherry high cells while DNA replication and cell 
cycle pathways were upregulated in mCherry low cells (Figure 2-4C). To determine 
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if cell cycle was associated with lower amounts of replication, we pulsed mice with 
BrdU, infected with scIAV-mCherry, and analyzed at 24 hpi. There was no increase 
in BrdU+ cells in the infected cell population, and BrdU+ cells made up only 0.6% 
of the mCherry low population (Figure 2-4D), suggesting that entry into the cell 
cycle is not driving restriction of viral replication.  
Cells with low or high levels of virus replication may differentially activate 
antiviral pathways. To determine the antiviral response we analyzed the 221 
differentially expressed ISGs and revealed several distinct groups of ISGs that 
varied with the level of virus replication (Figure 2-3C). Cluster 2 ISGs were highly 
induced in mCherry negative and low cells but not in mCherry high cells. This 
cluster included several genes with known antiviral activity against IAV including 
Eif2ak2 (PKR), TRIM56, and Pml (27, 132, 133). Cluster 4 was only induced in 
mCherry high cells (Figure 2-3C), suggesting that high levels of virus replication 
may produce a distinct antiviral response. Levels of Ifnar1 were similar in mCherry 
low and high cells (Figure 2-4E). Additionally, Mx1, which is IFN signaling-
dependent (32), was induced to a similar degree in mCherry low and high cells 
(Figure 2-4E), suggesting that differential extracellular IFN signaling alone may not 
drive the disparity in ISG expression. Expression of Irf7 was similar in all infected 
cells while Irf3 was decreased in mCherry high cells, suggesting that induction of 
these critical sensors is not driving the ISG disparity (Figure 2-4E). However, Ifnb1 
was higher in the mCherry high cells than other cell populations (Figure 2-4E). 





Figure 2-3. Unique antiviral signatures in cells supporting low and high levels of 
replication. Mice were infected with 105 pfu of scIAV-mCherry and live CD45-
CD31- mCherry negative, low, and high cells were profiled by mRNA-seq. (A) IAV cpm. 
(B) MDS of naïve and mCherry negative, low, and high cells based on host mRNA reads 
(C) Heatmap of 221 ISGs differentially expressed in the indicated populations. Cutoff of 





Figure 2-4. Unique transcriptional signatures in cells supporting low and high levels of 
replication. (A) IAV reads in mCherry high and low cells from each segment analyzed as 
ratio of total IAV reads. (B) IAV-PA reads were mapped in mCherry low or high cells. (C) 
 38 
Gene ontology enrichment analysis (DAVID, biological process) of genes with >2- or <-2-
fold change and FDR <0.05 over mCherry negative. Fold enrichment cutoff of FDR< 0.01. 
Red bars represent pathways that are shared between mCherry low and high cells. Black 
bars are unique pathways. (D) Mice were pulsed with BrdU and infected with scIAV-
mCherry. The percentage of BrdU+ in the mCherry- and mCherry+ populations (left) and 
the percentage of BrdU+ mCherry low or high cells (right) were determined at 24 hpi Data 
representative of 2 independent experiments with 3-4 mice per group. (E) Read cpm of (L 
to R) Ifnar1, Mx1, Irf7, Irf3, and Ifnb1 in the indicated cell populations. IFNas and IFNl2 
and 3 were not detected above 3 cpm in any cell population analyzed. 
 
Active virus replication imparts specific antiviral responses 
We hypothesized that the ISGs uniquely expressed in mCherry high cells 
are specific to conditions of unchecked viral replication and may represent a ‘last 
resort’ antiviral effort by the host. To identify cells harboring actively replicating 
virus, we developed a scIAV encoding destabilized GFP (destGFP) in place of HA. 
The half-life of this protein is only 2 h compared to over 24 h for the standard 
enhanced GFP (134). Due to this rapid degradation, any GFP+ cells detected in 
vivo must be the result of active virus replication (Figure 2-5A). Mice were infected 
with scIAV-GFP or scIAV-destGFP and CD45-CD31- lung epithelial cells were 
analyzed for GFP expression at 24 hpi. Less than 15% of the total scIAV-GFP-
infected epithelial cells were detected by scIAV-destGFP, suggesting that many wt 
GFP+ cells are no longer supporting active replication at this timepoint (Figure 2-
5B and 2-6A). GFP+ lung epithelial cells from mice infected with wt GFP- or 
destGFP-expressing viruses were isolated and their transcriptomes profiled by 
mRNA-seq. As expected, destGFP+ cells contained more IAV mRNA than wt GFP+ 
cells (Figure 2-5C). Cellular transcripts were analyzed by MDS and revealed 
significant differences in destGFP+ compared to wt GFP+ cells, primarily across the 
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second dimension (Figure 2-5D). GO analysis of downregulated pathways in the 
destGFP+ and wt GFP+ populations revealed the same cell adhesion, extracellular 
matrix and development pathways that were downregulated in mCherry low and 
high cells (Figure 2-6B). This concordance suggests that cells specifically 
decrease certain sets of genes in response to IAV infection.  
To assess the antiviral response generated in cells supporting active 
replication we analyzed ISG expression in sorted destGFP+, destGFP-, wt GFP-, 
and naïve cells (Figure 2-5E). Cluster 1 ISGs were specifically induced in wt GFP- 
and destGFP- cells. This expression pattern was similar to cluster 2 in the mCherry 
expression analyses (Figure 2-3). We compared these two clusters and found 
several overlapping genes (Figure 2-5F), many of which have been demonstrated 
to have direct antiviral activity against IAV (27, 132, 133, 135). There was also a 
cluster of ISGs that were only expressed in actively replicating cells (Figure 2-5E, 
cluster 4b), analogous to cluster 4 in Figure 2-3. We compared cluster 4b to the 
unique ISGs expressed in mCherry high cells and found a high level of 
concordance (Figure 2-5G). These data demonstrate that cells supporting high 
levels of active virus replication express a distinct set of ISGs that is not expressed 
in other infected cells. Overall, our analyses using scIAV-destGFP recapitulated 
results obtained using scIAV-mCherry revealing distinct antiviral signatures in cells 





Figure 2-5. Virus expressing destabilized GFP labels actively infected cells revealing 
distinct antiviral responses. (A) Model for the use of scIAV-destGFP to identify cells with 
actively replicating virus. (B) Mice infected with 105 pfu of scIAV-ctrl, -GFP, or destGFP 
and live, CD45-CD31- cells analyzed for GFP expression 24 hpi. Data representative of 3 
experiments with n=3-4 mice per group. (C and D) Live, CD45-CD31- GFP+ and GFP- cells 
were sorted and mRNA mapped to the mouse and IAV genome. (C) Normalized IAV reads 
in each of the sorted cell populations. (D) MDS plot of the indicated populations based on 
mRNA reads. (E) Heatmap of the 197 differentially expressed ISGs in the indicated 
populations. FDR < 0.05 used as a cutoff. (F) Venn diagram of genes from mCherry cluster 
2 in figure 2 and GFP cluster 1 in figure 3. (G) Venn diagram of genes from mCherry 
cluster 4 in figure 2 and GFP cluster 4b in figure 3. Only genes induced to >10cpm in at 
least one condition are shown.  
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Figure 2-6. Virus expressing destabilized GFP labels actively infected cells revealing 
distinct transcriptional responses. (A) Mice infected with either scIAV-GFP (top) or scIAV-
destGFP bottom and CD45-CD31- cells analyzed for GFP expression at 12, 24, and 48 
hpi. 24 hpi time point is from figure 3B. Y-axis side scatter (SSC). (B) Gene ontology 
enrichment analysis (DAVID, biological process) of genes with >2- or <-2-fold change and 
FDR <0.05 over the corresponding GFP-. Pathways with FDR<0.01 by are shown. Green 
indicates overlapping pathways between GFP+ and destGFP+. Black bars are unique 
pathways. 
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Tropism is altered by IFN during virus spread 
 During an infection, IAV spreads and new cells are infected despite a local 
antiviral and proinflammatory response. To label cells infected after the initiation 
of inflammation, we employed a sequential infection strategy using scIAVs with 
distinct fluorophores to model virus spread in vivo (Figure 2-7A). Lung epithelial 
cells were analyzed for mCherry expression 24 h after the second infection. There 
was a significant decrease in the overall number of mCherry+ cells in the sequential 
infection, indicating that the first infection induced an immune response that 
conferred some protection (Figure 2-7B and C). Interestingly, mCherry low and 
high cells were observed at similar proportions in single and sequential infection. 
To determine if there is a change in tropism during the second round of replication, 
mCherry+ cells were analyzed for markers of ciliated epithelial cells and type I 
alveolar (ATI) cells (CD24high and pdpn+, respectively). The frequency of 
mCherry+pdpn+ cells was similar in single and sequential infection. However, there 
was a significant decrease in the frequency of mCherry+CD24high cells in the 
sequentially infected animals compared to mice infected with scIAV-mCherry 
alone (Figure 2-7D). To elucidate the mechanisms of protection during the second 
round of infection, we sorted CD54-CD31- mCherry negative, low, and high cells 
from sequentially infected mice for mRNA-seq analysis. These data were 
compared to the single infection data shown in figure 2. MDS analysis of the host 
transcripts demonstrated significant differences between single and sequential 
infected cells along the second dimension (Figure 2-7E). GO analysis of the genes 
significantly downregulated in both mCherry low and high sequential infected cells 
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demonstrated enrichment in several pathways involved in ciliated epithelial cell 
maintenance and development (Figure 2-7F), further supporting the data in Figure 
2-7D. No pathways were significantly upregulated between single and sequentially 
infected cells. We hypothesized that the first round of replication drives an IFN 
response that enhances the protection of ciliated epithelial cells, but not ATI cells. 
To test this, mice were treated intranasally with IFNβ or IFNl and 16 h later 
challenged with scIAV-mCherry. ATI cells and ciliated epithelial cells were 
analyzed for mCherry expression. Both IFNβ and IFNl treatment led to a 
significant decrease in the frequency of infected ciliated epithelial cells but did not 
protect ATI cells (Figure 2-7G and Figure 2-8). These data suggest that tropism is 




Figure 2-7. Tropism is altered by IFNb during virus spread. (A) Model demonstrating 
sequential infection strategy. (B) Representative flow plot of (A). (C) Numbers of total 
mCherry+, mCherry low, and mCherry high cells in single and sequential infection. (D) 
Frequency of total and mCherry+ CD24high ciliated cells and pdpn+ ATI cells. (E) MDS plot 
of single infected mCherry negative, low, and high cells from figure 3 and mCherry 
negative, low, and high cells from sequential infection. (F) Gene ontology enrichment 
analysis (DAVID, biological process) of the downregulated mCherry low and high genes 
that were significantly different (FDR < 0.05) from single to sequential infection. (G) CD45-
CD31- cells from mice treated with IFNb and infected with scIAV-mCherry analyzed for 
total (black) or infected (red) pdpn+ and CD24high cells. B-D representative of 5 
experiments with n=3-4 mice per group. G representative of 3 experiments with n=3-4 





Figure 2-8. Tropism is altered by IFNl during virus spread. CD45-CD31- cells from mice 
treated with IFNl and infected with scIAV-mCherry analyzed for total (black) or infected 





Multiple studies using single-cell sequencing have revealed heterogeneity 
in IAV replication and the antiviral response in vitro (62, 111). These data are 
consistent with previous reports demonstrating stochasticity in single cell 
responses to infection (112, 136-138). Importantly, single cell-sequencing 
following synchronized and unsynchronized IAV infection revealed that duration 
and infectious dose are not responsible for the heterogeneity (62). Single cell in 
vivo analysis also demonstrated heterogeneity in virus replication and antiviral 
responses, although the number of epithelial cells analyzed was low (139). 
Consistent with previous findings, our data reveal heterogeneity in virus replication 
levels and the cellular response to IAV during the early stages of infection in vivo. 
While we cannot determine if these cellular changes are a cause or a consequence 
of replication disparity, they reveal that the antiviral signatures are not equal in all 
infected cells.  
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IFN-I and –III drive the expression of hundreds of ISGs, which can vary by 
cell type (140). A landmark series of studies demonstrated a paucity of individual 
ISGs that inhibit a diverse array of viruses (23, 24). IRF-1, Mx, and IFITM2/3 were 
among the few ISGs that were able to significantly blunt IAV infection and 
replication (24). Additionally, IAV grown in absence of ISGs tolerates more 
mutations, suggesting that multiple ISGs normally constrain the virus (141). We 
found a constellation of known anti-IAV ISGs expressed in mCherry low and 
negative cells that were absent in cells supporting active or high levels of 
replication. While only correlative, it is interesting to speculate that these may be 
protective combinations of ISGs and failure to induce these genes permits high 
levels of replication. In addition to host factors, replication disparity could be in part 
due to mutations in the viral genome that enhance resistance or susceptibility to 
IFN. As such, Du et al. recently identified several IAV mutations that lead to IFN 
sensitivity (142). Moreover, the basal expression of one or more ISG alone, or in 
combination with induced ISGs, could be driving the disparate levels of virus 
replication. mCherry high cells also have increased levels of IFNb expression 
compared to other populations of cells in the infected lung (Figure 2-4E). An 
alternative hypothesis is that autocrine IFN signaling alone, in combination with 
high levels of replication, or basal ISG levels could drive the distinct ISG 
responses. 
Our data reveal a distinct set of ISGs expressed in cells with high or active 
virus replication. These ISGs may represent a reserve set of genes that are only 
turned on in cells that fail to blunt replication. Interestingly, some of these genes 
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are chemokines and other inflammatory mediators, which may help to orchestrate 
an inflammatory response to control virus spread from these cells. It may be 
important to only express these genes when control of replication has failed to 
prevent immunopathology. In addition, pattern recognition receptor usage may be 
an underlying mechanism of this ISG signature. While RIG-I is thought to be the 
primary sensor for IAV in epithelial cells recent evidence demonstrates that MDA5 
is important for the cellular response (143). High levels of replication might be 
needed to activate both RIG-I and MDA5 and could act as an additional level of 
regulation to prevent aberrant activation of proinflammatory ISGs. 
Both immune and epithelial cells sense IAV in vivo (144), and responses 
can be dependent on the cell type. We have previously demonstrated that club 
cells, which survive virus replication, exhibit prolonged ISG signatures (145, 146). 
Our data demonstrate that IAV tropism changes over the course of infection. 
Ciliated cells were afforded greater protection from secondary infection compared 
to ATI cells. Importantly, this could only be discovered through an in vivo scIAV 
sequential infection strategy. While IFNb and IFNl can drive this selective 
protection, it is unknown if IFN-mediated protection is direct or indirect through 
other epithelial or innate immune cells. 
Here we demonstrate heterogeneity in the levels of virus replication in vivo. 
Using two different virus reporters we reveal that distinct sets of antiviral genes are 
expressed in cells harboring low and high levels of virus replication. Through a 
sequential infection strategy, we demonstrate that virus tropism is altered during 
virus spread where ciliated epithelial cells have augmented protection from 
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infection. These results demonstrate a dynamic environment within tissues that is 
driven by both virus replication levels and the cell type infected. 
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CHAPTER 3: Cell type- and replication stage-specific influenza virus 
responses in vivo 
 
SUMMARY 
Influenza A viruses (IAVs) remain a significant global health burden. 
Activation of the innate immune response is important for controlling early virus 
replication and spread. It is unclear how early IAV replication events contribute to 
immune detection. Additionally, while many cell types in the lung can be infected, 
it is not known if all cell types contribute equally to establish the antiviral state in 
the host. Here, we use single-cycle IAVs (scIAVs) to characterize the early immune 
response to IAV in vitro and in vivo. We found that the magnitude of virus 
replication contributes to antiviral gene expression within a cell prior to the 
induction of a global response. We also developed a scIAV that is only capable of 
undergoing primary transcription, the earliest stage of virus replication. Using this 
tool, we uncovered replication stage-specific responses in vitro and in vivo. Using 
innate immune receptor knockout cells, we identify RIG-I as the predominant 
antiviral detector of primary virus transcription and amplified replication in vitro. 
Using a Cre-inducible reporter mouse, we used scIAVs expressing Cre-
recombinase to characterize cell type-specific responses in vivo. Individual cell 
types upregulate unique sets of antiviral genes in response to both primary virus 
transcription and amplified replication. We also identified antiviral genes that are 
only upregulated in response to direct infection. Altogether, these data offer insight 




Influenza A virus (IAV) is a seasonal pathogen that causes significant global 
morbidity and mortality annually. Respiratory epithelial cells are the primary targets 
of IAV. Infected epithelial cells play a critical role in detecting IAV and activating 
the interferon (IFN) response. Failure of infected cells to control IAV replication can 
lead to cell death and spread of the virus to neighboring cells, resulting in 
significant damage to the lung epithelium and severe disease symptoms. The 
primary innate immune receptor responsible for detection of IAV infection in 
epithelial cells is retinoic acid inducible gene-I (RIG-I). Detection through another 
RIG-I-like receptor (RLR), melanoma differentiation-associated protein 5 (MDA5), 
has also been shown to contribute in vivo but not in ex vivo studies (143, 147). 
While many epithelial cell types can be infected throughout the course of infection, 
it is unknown if all infected cell types contribute equally to establish the antiviral 
state in the host. 
IAV has a segmented, negative-sense RNA genome. Each of the eight gene 
segments are packaged into virions in complex with the heterotrimeric viral RNA-
dependent RNA polymerase (RdRp). Upon infection, these viral ribonucleoprotein 
(vRNP) complexes traffic to the nucleus where the RdRp both transcribes the viral 
RNA (vRNA) to generate messenger RNA (mRNA) and replicates the vRNA 
through a positive sense complementary RNA (cRNA) intermediate (148). While 
the exact mechanism for how the virus balances between transcription and 
replication for each gene segment is unknown, replication requires de novo 
polymerase complexes to stabilize the cRNA intermediate (149-152), suggesting 
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that transcription occurs prior to replication. Additionally, amplification of vRNA has 
been shown to be required for induction of type I IFN, suggesting early IAV 
infection is poorly detected by the innate immune system (150, 153). Several 
groups have described aberrant vRNA products, including defective interfering 
genomes and mini viral RNAs, as the predominant inducers of innate immune 
activation through RIG-I (8, 154, 155). When these RNAs are produced during the 
course of an infection has not been well defined.  
Previous methods to assess distinct stages of early virus replication within 
a cell have used drugs such as actinomycin D or cycloheximide to inhibit 
transcription or translation (155-157). These drugs also inhibit host cell processes, 
limiting the ability to analyze the host response. We therefore used a series of 
viruses genetically restricted in progressing through different stages of replication. 
Single-cycle IAVs (scIAVs) lacking hemagglutinin protein and unable to spread 
were used to elucidate mechanisms of innate immune activation during the early 
stages of IAV infection in mice. We identified unique responses to the magnitude 
of replication during direct infection in vivo. Additionally, we generated a genetically 
restricted a scIAV such that only primary transcription can occur. Entry and primary 
transcription alone are detected by RIG-I and drive an antiviral response in vitro. 
Using this tool, we uncovered epithelial cell type-specific responses to primary 
virus transcription and amplified virus replication in vivo. Altogether, these data 
demonstrate that the antiviral response to IAV is sensitive to the stage of 
replication and varies across cell types.  
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MATERIALS AND METHODS 
Tissue culture 
Human embryonic kidney 293T (293T, ATCC) cells, human lung 
adenocarcinoma A549 cells, Madin-Darby canine kidney (MDCK) cells, and MDCK 
cells expressing IAV-WSN HA (WSN-HA MDCK, kind gift from Dr. Adolfo García-
Sastre, Mount Sinai) were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) with 1% fetal bovine serum (FBS) and 1% penicillin-streptomycin. MDCK 
cells expressing IAV-PR8 HA (PR8-HA MDCK, kind gift from Dr. Luis Martinez-
Sobrido, University of Rochester) were supplemented with 125 µg/mL of 
hygromycin B. 
 
Generation of PR8-PB1 MDCK cells  
The PR8-PB1 coding sequence was cloned into the NotI-digested pLEX-
MCS lentivirus packaging vector (kind gift from Dr. Wade Bresnahan, University of 
Minnesota) using In-Fusion cloning (Takara). The lentivirus packaging vector and 
the pMDG and p∆NRF helper plasmids were transfected into 293T cells using the 
Lipofectamine 3000 transfection reagents (Invitrogen). At 24 and 48 hours post-
transfection, supernatant was harvested and filtered through a 0.45 µm PES filter. 
A GFP lentivirus (GFP-lenti) was generated as a control to determine the 
approximate titer of the PB1-lenti stock. MDCK cells were transduced with 10-fold 
serial dilutions of GFP-lenti to determine titer. MDCK cells were transduced with 
PB1-lenti at an MOI=0.5. After 48 hours, the cells were diluted to obtain single-cell 
clones. Positive clones were selected for and maintained in Dulbecco’s modified 
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Eagle’s medium (DMEM) with 1% fetal bovine serum (FBS), 1% penicillin-
streptomycin, and 5 µg/mL puromcyin. Integration of the lentivirus transgene was 
verified by western blot (rabbit anti-PB1, PA5-34914, ThermoFisher Scientific) and 





Viruses were rescued in 293T cells using the IAV-PR8 plasmid-based 
transfection system in the pDZ vector. scIAV-∆HA viruses were generated as 
previously described (158). To generate scIAV-∆PB1 viruses, mCherry or Cre 
recombinase (Cre) was inserted between the 5’ and 3’ packaging signals of PR8 
PB1 (100 and 200 bp, respectively). Plasmids were transfected at 500ng/reaction 
onto 293T cells in Opti-MEM using Lipofectamine 2000 (Invitrogen) and incubated 
at 37ºC. pCAGGs-WSN-PB1 or -WSN-HA were supplemented into each reaction. 
After 24 hours, PR8-PB1 MDCK or WSN-HA MDCK cells were added to 
transfected wells in Opti-MEM containing 0.5µg/mL TPCK-trypsin. Reactions were 
supplemented at 24 and 48 hours after cell overlay with 500µL of Opti-MEM 
containing 1-2µg/mL TPCK trypsin. Seventy-two hours after cell overlay, the 
supernatant was harvested, centrifuged to remove cellular debris, and stored at -
80ºC. Viruses were plaque purified and amplified on either PR8-PB1 or PR8-HA 
MDCK cells. Viral sequences were confirmed using Sanger sequencing. Virus 
stocks were tittered via plaque assay. Infections were performed in infection media 
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(PBS with 10% Ca/Mg, 1% pen/strep, 5% BSA) at 37ºC on either PR8-PB1 or 
WSN-HA MDCK cells. After 1hr, infection media was replaced with an agar overlay 
(2xMEM, 1µg/mL TPCK-trypsin, 1% DEAE-dextran, 5% NaCO3, 2% oxoid agar) 
and cultured for 40-42hrs at 37ºC. Plaques were fixed with 4% formaldehyde for 
30 minutes prior to removal of the overlay. Blocking and immunostaining were 
performed at room temperature for 1 hour in 5% milk in PBS. The following 
antibodies were used in staining: polyclonal anti-IAV PR8/34, 1:5000 (V301-511-
552), Peroxidase Rabbit Anti-Chicken IgG, 1:5000 (303-035-003, Jackson 
Immuno Research). Virus plaques were detected using TruBlue Peroxidase 
Substrate (50-547-28, Kirkegard & Perry Laboratories). 
 
Stranded next-generation sequencing of A549 cells 
Infections were performed in A549 cells in infection media at an MOI of 1. 
Infections were synchronized at 4ºC for 30 minutes then transferred and incubated 
at 37ºC. The zero hour time point was harvested after 30 minutes at 37ºC and 
additional time points were harvested at 3, 6, 9, 12 hours post infection. RNA was 
extracted using TRIzol. The cDNA libraries were prepared using the Stranded 
Total RNA v2 Pico Mammalian kit (Takara). Samples were sequenced as 150 base 
pair paired-end reads using NovaSeq (Illumina). The customized influenza 
A/PR/8/34/(H1N1) mRNA sequence and annotation were used for mapping 
(available upon request). The forward and reverse virus reads counts were 
obtained by using FeatureCounts -s parameter (118). The strand specific reads of 
individual viral genes were summed as either negative or positive strand reads 
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sample by sample, respectively. To normalize the strand specific viral reads, we 
first generated the forward or reverse strand reads ratio by using total viral reads 
as denominator. The ratio of forward or reverse strand reads were then normalized 
against total mapped reads (relative library size), which were subsequently 
transformed into counts per million. All RNA sequencing files are available from 
the NCBI GEO database (accession number GSE147832 ). 
 
Western blot analysis 
Viral stocks were lysed and separated by SDS-PAGE (2-15% gel). Protein 
was transferred to a nitrocellulose membrane at 4ºC for 2 hours and blocked with 
5% milk in PBS. The membrane was incubated with primary antibodies rabbit anti-
PB1 (1:1000, PA5-34914, ThermoFisher Scientific) followed by goat anti-rabbit 
IgG horseradish peroxidase-conjugated secondary antibody (1:1000, 
ThermoFisher Scientific). Images were obtained using a Li-Cor Odyssey Fc 
imaging system. 
 
Detection of defective interfering particles in scIAV stocks 
RNA was extracted from viral stocks, including an A/Puerto Rico/8/34 stock 
grown in MDCK cells. RNA was extracted using the NucleoSpin Virus Kit 
(Macheray-Nagel). RNA was reverse transcribed to cDNA using the SuperScript 
III One-Step RT-PCR with Platinum Taq (Invitrogen). PB2 and NA gene segments 
were amplified from each sample as well from a pDZ-PR8-PB2 or NA plasmid 





GTAGCAGCAGTAGAAACAAGGAGTTTTT-3’. The samples were loaded and run 
on a 1% agarose gel with 0.012% ethidium bromide in Tris-acetate-EDTA buffer. 
Images were obtained using a GelDoc EZ Imager (BioRad). 
 
Next-generation mRNA sequencing of A549 knockout cells 
NTC and knockout A549 cells (kind gift from Michael Gale, Jr., University of 
Washington) were infected with ∆HA-mCherry or ∆PB1-mCherry at MOI=1. Cells 
were harvested at 12 hpi and RNA extracted using the RNeasy PLUS Micro kit 
(Qiagen). cDNA libraries were prepared using the TakaraBio PicoMammalian kit 
and sequenced as 150 base pair paired-end reads using NovaSeq (Illumina). The 
raw sequencing reads were mapped to human genome (GRCh38) using Bowtie 
aligner (bowtie2 version 2.3.4.1) with local mode, 22 nt seed sequence, and ≤1 nt 
mismatch (-L 22 and -N 1 parameters) (116). The mapped reads were then 
assigned to Ensembl gene model (Homo_sapiens.GRCh38.87.gtf) with 
featureCounts of the Subread software package (version 1.5.1) (118). The raw 
reads count tables were merged to generate data matrix and used for subsequent 
statistical analysis. To obtain significant differentially expressed genes, the 
experimental groups by design were compared to control group (naïve) and the 
edgeR (version 3.24.3) of bioconductor package was used for statistical analysis 
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(121, 122). Raw reads were normalized by using default method in the package 
prior to generating stats. 
 
Mice and virus infection 
Wild-type C57BL/6J and B6.Cg-Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/J mice 
were purchased from The Jackson Laboratory. Mice were infected intranasally 
(i.n.) with 105 pfu of scIAV unless otherwise indicated. All experiments involving 
mice were performed as dictated by the University of Minnesota Institutional 
Animal Care and Use Committee. 
 
Flow cytometry 
Mice were euthanized and lungs were inflated with 2 mL dispase (Corning) 
and 0.5 mL 1% low melt agarose (Lonza) and allowed to sit covered with an ice 
pack for two minutes. Lungs were then removed from mouse and transferred to 1 
mL dispase and incubated at room temperature for 45 minutes. Next, lungs were 
incubated in DMEM with DNase I (Sigma-Aldrich) at 95 U/mL and shaken for 10 
minutes at room temperature. Lungs were homogenized in GentleMACS 
dissociator and red blood cells were lysed with ACK buffer. Cells were filtered to 
obtain a single cell suspension prior to staining. Cells were stained with Ghost Dye 
Red 780 (Tonbo), followed by the following antibodies against surface markers: 
CD45 (30-F11), podoplanin (clone 8.1.1), CD24 (M1/69), EpCAM (CD324, clone 
G8.8), MHCII (I-A/I-E, clone M5/114.15.2) (Biolegend), and CD31 (clone 390, BD 
Bioscience). Cell counts were obtained using AccuCheck counting beads 
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(Thermofisher Scientific). Data were acquired on a BD LSRFortessa (Becton 
Dickinson, San Jose, CA). 
 
Next-generation mRNA sequencing of sorted mouse lung epithelial cells 
C57Bl/6 mice were infected and mCherry negative, low, and high CD45-
CD31- cells were FACS sorted. B6.Cg-Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/J mice 
were infected and the following samples were FACS sorted: tdTomato+ ciliated 
cells (CD24hi podoplanin-), type I alveolar cells (CD24- podoplanin+), and type II 
alveolar cells (CD24- podoplanin- MHCII+ EpCAM+), and tdTomato- ciliated cells 
and type I and II alveolar cells. RNA was isolated from samples using the RNeasy 
Plus Micro kit (Qiagen). cDNA libraries were prepared using the TakaraBio 
PicoMammalian kit and were sequenced as 50 base pair paired-end reads using 
NovaSeq (Illumina). The raw sequencing reads were mapped to mouse genome 
(GRCm38) using Bowtie aligner (bowtie2 version 2.3.4.1) with local mode, 22 nt 
seed sequence, and ≤1 nt mismatch (-L 22 and -N 1 parameters) (116). The 
mapped reads were then assigned to Ensembl gene model 
(Mus_musculus.GRCm38.87.gtf) accordingly with featureCounts of the Subread 
software package (version 1.5.1) (118). For flu reads mapping and assignment, 
the customized influenza A/PR/8/34/(H1N1) mRNA sequence and annotation were 
used. The raw reads count tables were merged to generate data matrix and used 
for subsequent statistical analysis. To obtain significant differentially expressed 
genes, the experimental groups by design were compared to control group (naïve) 
and the edgeR (version 3.24.3) of bioconductor package was used for statistical 
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analysis (121, 122). Raw reads were normalized by using default method in the 
package prior to generating stats. 
 
Statistical analysis 
Statistical analyses were completed using GraphPad Prism 7 software. 
Comparisons between two groups were executed using a two-tailed Student t test. 
Comparisons between more than two groups were completed using a one-way 
ANOVA. Additional tests were performed where indicated. Error bars were 
calculated using SEM. 
 
Ethics statement 
Care and use of the animals was in accordance with the Guide for the Care 
and Use of Laboratory Animals from the National Research Council and the USDA 
Animal Care Resource Guide. All experimental protocols involving the use of mice 
were approved by the Institutional Animal Care and Use Committee at the 




Heterogeneous antiviral response to early IAV infection in vivo 
We have previously used a single-cycle influenza virus (scIAV) expressing 
mCherry in place of the coding sequence for the hemagglutinin (HA) segment 
(∆HA-mCherry) to uncover replication heterogeneity during the early stages of IAV 
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infection in mice (158). Other groups have found similar heterogeneity at early 
timepoints in vitro (62, 63, 160, 161), as well as heterogeneity in the ability to 
induce IFN production in infected cells (63, 112, 162, 163). Our previous analyses 
were unable to distinguish genes induced directly by virus infection from those 
driven by IFN and inflammation. To address this, we assessed an earlier time 
point, 12 hours post-infection (hpi), where distinct populations of mCherry high and 
low epithelial cells were still observed in vivo (Figure 3-1A). To determine if 
mCherry high and low cells display distinct antiviral signatures, we infected mice 
with ∆HA-mCherry and sorted mCherry high, low, and negative epithelial cells at 
12 hpi for mRNA-seq analysis. Similar to 24 hpi, at 12 hpi reads mapping to the 
IAV genome were higher in the mCherry high cells than in mCherry low cells, 
validating the use of mCherry fluorescence as an indicator of scIAV replication at 
12 hpi (Figure 3-1B). Multidimensional scaling (MDS) of host mRNAs revealed 
significant differences between the mCherry high and low populations (Figure 3-
1C). However, there is no difference between the mCherry negative and naïve 
populations, suggesting that alterations in host gene expression in mCherry+ cells 
at 12 hpi are driven directly by virus replication, rather than a global inflammatory 
response. Moreover, mCherry high and low cells display distinct antiviral gene 
signatures (Figure 3-1D). While the genes analyzed in this study are designated 
as IFN-simulated genes (ISGs), IFN-independent upregulation by virus replication 
of some of these genes has been described (31-33) and we do not distinguish 
between virus-induced and IFN-induced. The putative protective ISGs found in the 
mCherry low cells at 12 hpi overlap with the genes identified using both ∆HA-
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mCherry and ∆HA-destabilized GFP at 24 hpi identified previously (158) (Figure 3-
1E, top, S1Table). Among these are genes such as Eif2ak2 (PKR) which has well-
described antiviral activity during IAV infection (27), as well as genes that have not 
been described to have anti-IAV activity, such as Helz2. We also found overlap in 
the genes upregulated in cells with high levels of virus replication (Figure 3-1E, 
bottom, Table 3-2), including the chemokines Cx3cl1, Cxcl11, and Ccl5. Gene 
ontology (GO) analysis of genes significantly upregulated over naïve in mCherry 
high and low cells revealed that only high levels of virus replication induce 
apoptosis pathways at 12 hpi (Figure 3-1F). Induction of these ISGs may require 
high levels of replication as a way to tightly regulate a pro-inflammatory and pro-
apoptotic response, making these ISGs a “reserve” set of genes that are only 
upregulated when other mechanisms of control have failed. These data further 
suggest that pathologic responses may be driven from only a small subset of 
infected cells. Altogether, these data suggest that the replication and response 
heterogeneity observed early during IAV infection is established prior to the 






Figure 3-1. Heterogeneous antiviral response to scIAV infection at 12 hpi. B6 mice were 
infected with 105 PFU of scIAV-HA-mCherry or 103 PFU PR8. (A) CD45-CD31- cells were 
analyzed for mCherry expression at 12 hpi. Data representative of six independent 
experiments with n=3-4 mice per group. mCherry negative, low, and high CD45-CD31-
cells were sorted at 12 hpi for mRNA-seq analysis. (B) IAV CPM (C) MDS of naïve and 
 64 
mCherry negative, low, and high cells. (D) Heatmap of 207 ISGs differentially expressed 
in the indicated populations. Cutoff of false discovery rate (FDR) is ≤ 0.05. (E) Overlapping 
low ISGs (mCherry 24h cluster 2, GFP cluster 1, and mCherry 12h clusters 1 and 5) and 
high ISGs (mCherry 24h cluster 4, GFP cluster 4b, and mCherry 12h cluster 8). Only 
genes induced to ≥10 CPM in at least one sample are shown. (F) Gene ontology analysis 
(DAVID, biological processes) was performed for genes upregulated in mCherry high, low, 
and negative cells over naïve (logFC ≥ 1.5, FDR ≤ 0.05). Unique pathways identified in 
mCherry low (top) mCherry high (bottom) are shown (FDR ≤ 0.05). (B-F) representative 
of one experiment with n=3 mice per group. 
 













Unc93b1 Lap3 Adar Lamp3 Adar Oas3
Adar Lrg1 Alyref Lgmn Birc3 Parp12
Bag1 Ncf1 Ankfy1 Map3k5 Ddx58 Pml
Casp7 Nmi B4galt5 Max Ddx60 Pnpt1
Ccnd3 Pml Bag1 Mov10 Eif2ak2 Prkd2
Cd74 Psmb9 Birc3 N4bp1 Fam46a Rnf114
Ddx58 Pxk Ccl2 Ncf1 Helz2 Rnf213
Eif2ak2 Rab27a Ccnd3 Optn Herc6 Sp110
Fbxo6 Rnf213 Cd9 Pi4k2b Ifi27 Spats2l
Glipr2 Serpinb9 Chmp5 Pml Ifi27l2a Stat1
Glrx Stat1 Commd3 Pnpt1 Ifi35 Stat2
Helz2 Stat2 Ehd4 Ptma Ifit1bl1 Steap4
Ifi27 Tap1 Eif2ak2 Rab27a Irf2 Tdrd7
Ifi44 Tnfsf10 Eif3l Rbm25 Irf9 Trim14
Irf9 Uba7 Epas1 Rpl22 Isg20 Trim25
Lamp3 Ext1 Rtcb Lgmn Trim5
Fam46a Slfn5 Mov10 Trim56
Fbxo6 Sptlc2 N4bp1 Uba7
Fndc3b Sqle Nmi Unc93b1








∆HA-mCherry 24 hpi cluster 2 ∆HA-destGFP cluster1∆HA-mCherry 12 hpi clusters 1 and 5
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Genetic restriction of IAV to primary transcription 
We hypothesized that the heterogeneous scIAV replication is due to 
differential ability of cells to detect and respond to the very early stages of virus 
replication. We therefore developed a scIAV that is unable to progress from 
primary transcription to replication. We replaced the coding sequence for 
polymerase basic 1 (PB1) with the coding sequence for mCherry (∆PB1-mCherry). 
This virus is grown in a cell line that expresses PB1 protein. The resulting viruses 
package complete RdRps but cannot generate new polymerase complexes in 
Abtb2 Junb Abtb2 Lgals3 Arg2 Nfil3
Alyref Lgals9 Atf3 Mafb Ccl5 Odc1
Arg2 Ly6e Atp10d Maff Cd74 Pim3
Atf3 Mafb Ccl5 Marcksl1 Cx3cl1 Psmb8
B2m Maff Cdkn1a Mcl1 Ddit4 Ripk2
Bst2 Map3k14 Csrnp1 Nup50 Gem Rnf24
Ccl5 Marcksl1 Cx3cl1 Odc1 Glipr2 Sat1
Cd274 Max Ddit4 Pim3 Ifi30 Serpine1
Cdkn1a Mx1 Fam134b Ripk2 Lrg1 Slc16a1
Ceacam1 Mx2 Fam46c Rnf19b Marcksl1 Slc1a1
Csrnp1 Myd88 Gem Sat1 Max Tmem140
Cx3cl1 Nampt Gpx2 Serpine1





















∆HA-mCherry 12 hpi cluster 8 ∆HA-mCherry 24 hpi cluster 4 ∆HA-destGFP cluster 4b
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infected cells. Therefore, any de novo RNA generated in infected cells is being 
produced only by incoming virus RdRps. We first quantified levels (+)-sense 
(m/cRNA) and (-)-sense (vRNA) generated by ∆HA-mCherry and ∆PB1-mCherry 
at 0, 3, 6, 9, and 12 hpi in A549 cells. We found that while both viruses can produce 
(+)-sense RNA, scIAV-∆PB1-mCherry cannot amplify (-)-sense vRNA (Figure 3-
2A), validating ∆PB1-mCherry as a tool to assess the immune response to primary 
IAV transcription.  
We hypothesized that, due to the different RNA species generated, ∆HA 
and ∆PB1 viruses would induce distinct immune responses. Importantly, ∆HA-
mCherry and ∆PB1-mCherry virus stocks contain equal amounts of defective 
interfering (DI) genomes (Figure 3-2B), which have been shown to induce RIG-I 
activation independent of viral protein synthesis (155). Additionally, ∆HA and ∆PB1 
viruses package equivalent PB1 protein (Figure 3-2C). Therefore, any differences 
in immune activation are due to differences in the de novo RNA generated by the 






Figure 3-2. Genetic restriction of IAV to primary transcription. (A) A549 cells were infected 
with ∆HA-mCherry or ∆PB1-mCherry at MOI=1 and harvested at the indicated timepoints 
for RNA-seq. Positive sense (m/cRNA) and negative sense (vRNA) RNA was quantified. 
Data representative of two independent experiments with n=3 replicate samples per 
group. (B) vRNA was extracted from the indicated virus stock and PB2 (top) and NA 
(bottom) were amplified. Representative of two independent experiments. (C) 1.24x105 
PFU of ∆PB1-Cre and ∆HA-Cre virus were analyzed for PB1 protein. Representative of 
three independent experiments. 
 
 
Primary transcription is detected by RIG-I in vitro 
RIG-I and not MDA5 has been reported to recognize IAV infection in primary 
mouse fibroblasts (147) but the processes of the viral infection and replication 
cycle that contribute to this recognition are not known. To understand how ∆PB1-
mCherry is being detected by infected cells, we infected RIG-I-/-, MDA5-/-,        
MAVS-/-, and non-targeted control (NTC) A549 cells (164) with ∆PB1-mCherry or 
∆HA-mCherry and harvested cells for mRNA-seq analysis at 12 hpi. Importantly, 
naïve knockout cells do not display significant differences in overall gene 
expression compared to naïve NTC cells (Figure 3-3). Compared to naïve cells, 
both viruses robustly induce antiviral gene expression in NTC cells (Figure 3-4A).  
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This induction is ablated in RIG-I-/- and MAVS-/- cells. There are no genes 
significantly upregulated (FDR≤0.05, logFC≥2 over naïve, logCPM≥1) in ∆PB1-
infected RIGI-/- cells (Table 3-3). In contrast, infected MDA5-/- cells upregulated 
ISGs nearly to the same extent as NTC cells (Figure 3-4A). In both NTC and   
MDA5-/- cells, ∆HA infection robustly upregulates IFNB and IFNL3 (Figure 3-4B). 
Albeit to a much lower degree, ∆PB1 infection also significantly upregulates these 
IFNs (logFC≥2 over naïve, FDR≤0.05). These data indicate that RIG-I is required 
for detecting both primary transcription and amplified replication and that primary 
transcription is sufficient to induce IFN.  
 
Figure 3-3. Basal gene expression between knockout cell lines. Individual gene 
expression values (CPM) for naïve NTC A549 cells were plotted against naïve RIG-I-/- 
(left), MDA5-/- (middle), and MAVS-/- (right) A549 cells. R-squared values were calculated 





Figure 3-4. Primary transcription is detected by RIG-I in vitro. Indicated A549 cells were 
infected with ∆HA-mCherry or ∆PB1-mCherry at MOI=1 and RNA extracted at 12 hpi for 
mRNA-seq analysis. (A) Total (black) and ISGs (red) differentially expressed genes are 
shown. The number of genes significantly upregulated (logFC≥2, FDR≤0.05, log CPM≥1) 
over naïve is shown in upper right of plot. (B) Read CPM for IFNB1 and IFNL3 in naïve 
and ∆HA-mCherry or ∆PB1-mCherry infected A549 cells. Data representative of one 











Table 3-3. Stage-specific, RLR-dependent ISG expression in vitro.   
 
 
Detection of cells supporting only primary transcription in vivo 
While we were able to detect virus mRNA by RNA-seq, we were unable to 
detect mCherry fluorescence in A549 cells infected with ∆PB1-mCherry (Figure 3-
5A). The mCherry gene segment is appropriately packaged, as co-infection with 
wt IAV to trans-complement PB1 results in mCherry fluorescence. Due to the 
limited ability to detect ∆PB1-mCherry in vitro, we developed additional scIAVs for 
in vivo analysis. These viruses express Cre recombinase (Cre) in place of either 
HA or PB1 (∆HA-Cre and ∆PB1-Cre, respectively). Cre-inducible reporter mice 
have previously been used to identify cells infected with IAV expressing Cre (41, 
145, 146). This system allows for the tracking of infected cells via a Cre-inducible 
host-endogenous fluorophore, tdTomato. Therefore, detection of infected cells is 
APOL1 MIR22HG APOL6 IRF7 AC007952.4 HSPA6 AC005682.1 ISG20 AP003119.3 MX1 AC005682.1 IFIT2 IFIT1 MX1
APOL2 MX1 BATF2 ISG15 ATF3 MIR22HG AC007952.4 KLF4 APOL1 MX2 AC007952.4 IFIT3
APOL6 MX2 C19orf66 ISG20 BEST1 MXD1 ADM LINC00641 APOL6 MYD88 ATF3 LINC00641
ATF3 MXD1 CCL5 MX1 DDIT3 NEB APOL1 MAFF BATF2 NLRC5 BEST1 MIR22HG
BATF2 MYD88 CMPK2 MX2 DNAJB9 NR4A3 APOL2 MIR22HG C19orf66 OAS1 CCL2 MSX1
BEST1 NEB DDX58 OAS1 DUSP6 NUP210L APOL6 MSX1 CCL5 OAS2 DDIT3 MX1
C19orf66 NLRC5 DDX60 OAS2 FBXW10 RND1 ATF3 MX1 CMPK2 OAS3 DNAJB9 MXD1
CCL2 NUP210L DTX3L OAS3 FOS SPRY4 BATF2 MX2 DDX58 OASL DUSP6 NEB
CCL5 OAS1 GBP1 OASL GDF15 TNFRSF10D BEST1 MXD1 DDX60 PARP10 EGR1 NUP210L
CD274 OAS2 GBP3 PARP10 HBEGF VTRNA1-3 C19orf66 MYD88 DTX3L PARP12 FBXW10 OASL
CMPK2 OAS3 HELZ2 PARP12 HERPUD1 CCL2 NEB FAM46A PARP14 FOS PMAIP1
DDIT3 OASL HERC5 PARP14 CCL5 NLRC5 GBP1 PARP9 GADD45A RND1
DDX58 PARP10 HERC6 PARP9 CD274 NR4A3 HELZ2 PLEKHA4 GDF15 SPRY4
DDX60 PARP12 IFI16 PLEKHA4 CITED2 NT5C3A HERC5 PLSCR1 HBEGF TNFAIP3
DNAJB9 PARP14 IFI27 PLSCR1 CMPK2 NT5C3AP1 HERC6 PML HERPUD1 TNFRSF10D
DTX3L PARP9 IFI35 RASGRP3 DDIT3 NUP210L IFI16 RASGRP3 HSPA6 VTRNA1-3
DUSP6 PLEKHA4 IFI44 RSAD2 DDX58 OAS1 IFI27 RSAD2 IFIT1
EGR1 PLSCR1 IFI44L SAMD9 DDX60 OAS2 IFI35 SAMD9
FAM46A PMAIP1 IFI6 SAMD9L DNAJB9 OASL IFI44 SAMD9L
FOS PML IFIH1 SP110 DTX3L PARP10 IFI44L SP110
FOSB PPM1K IFIT1 STAT2 DUSP6 PARP12 IFI6 STAT1
FST PPP1R15A IFIT2 TRANK1 EGR1 PARP14 IFIH1 STAT2
GBP1 PSMB9 IFIT3 TRIM21 FAM46A PARP9 IFIT1 TAP1
GBP3 PYGM IFIT5 TRIM22 FBXW10 PLEKHA4 IFIT2 THEMIS2
GDF15 RASGRP3 IFITM3 USP18 FOS PLSCR1 IFIT3 TRANK1
HBEGF RND1 GADD45A PMAIP1 IFIT5 TRIM14
HELZ2 RSAD2 GBP1 PML IFITM3 TRIM21
HERC5 SAMD9 GBP3 PPM1K IRF7 TRIM22
HERC6 SAMD9L GDF15 PPP1R15A ISG15 UBE2L6
HERPUD1 SAMHD1 HBEGF PTGS2 ISG20 USP18
HSPA6 SERTAD1 HELZ2 RASGRP3
IFI16 SLC10A1 HERC5 RND1
IFI27 SLC16A12 HERC6 RSAD2
IFI35 SLFN5 HERPUD1 SAMD9
IFI44 SP100 HSPA6 SAMD9L
IFI44L SP110 IFI16 SLFN5
IFI6 SPRY4 IFI35 SP110
IFIH1 STAT2 IFI44 SPRY4
IFIT1 TAP1 IFI44L STAT2
IFIT2 THEMIS2 IFI6 TAP1
IFIT3 TNFAIP3 IFIH1 THEMIS2
IFIT5 TNFRSF10D IFIT1 TNFAIP3
IFITM3 TRANK1 IFIT2 TNFRSF10D
IFNL1 TRIM21 IFIT3 TRANK1
IRF1 TRIM22 IFIT5 TRIM21
IRF7 TRIM38 IFITM3 TRIM22
ISG15 TRIM69 IFNB1 TRIM38
ISG20 UBE2L6 IFNL1 TRIM69
KCNB1 USP18 IL6 UBE2L6




A549 NTC A549 RIG-I-/- A549 MDA5-/- A549 MAVS-/-
∆PB1-mCherry∆HA-mCherry ∆HA-mCherry ∆PB1-mCherry ∆HA-mCherry ∆PB1-mCherry
 71 
not dependent on high levels of active virus replication. tdTomato+ lung epithelial 
cells can be detected at 24 hpi with either ∆HA-Cre or ∆PB1-Cre (Figure 3-5B). 
However, the geometric mean fluorescence intensity (gMFI) of tdTomato is higher 
in ∆PB1-Cre infected mice (Figure 3-5C). As tdTomato is a host-endogenous 
fluorophore, this gMFI difference could reflect differences in the ability of ∆HA and 
∆PB1 viruses to induce shut-off of host transcription/translation. Using cell type-
specific markers, we identified infected ciliated cells (CD24hi podoplanin-), type I 
alveolar cells (ATI; CD24- podoplanin+), and type II alveolar cells (ATII; CD24- 
podoplanin- MHCII+ EpCAM+) (Figure 3-6A). There are overall fewer tdTomato+ 
cells following ∆HA-Cre infection, likely due to more robust cell death from full 
replication compared to ∆PB1-Cre infection (Figure 3-5D). However, the proportion 
of each epithelial cell type within the tdTomato+ population was the same in the 
two infections (Figure 3-5E, Figure 3-6B), suggesting these cell types are equally 
susceptible to infection-induced cell death. All ∆HA-Cre infected cell types show 
lower tdTomato gMFI compared to ∆PB1-Cre infected cells. Intriguingly, ∆HA-Cre 
infected ciliated cells show reduced gMFI compared to total ∆HA-Cre tdTomato+ 
cells. Similarly, ∆PB1-Cre infected ATI and ciliated cells show reduced tdTomato 
gMFI compared to total tdTomato+ cells (Figure 3-6C), suggesting that there are 





Figure 3-5. Detection of cells supporting only primary transcription in vivo. (A) A549 cells 
were infected with ∆HA-mCherry, ∆PB1-mCherry, or ∆PB1-mCherry and PR8 at MOI=1 
and analyzed at 24 hpi by flow cytometry. Representative of 3 independent experiments 
with n=1 sample replicate per group. (B-E) Cre reporter mice were infected with 103 PFU 
of PR8 or 105 PFU of ∆HA-Cre, or ∆PB1-Cre and lungs analyzed by flow cytometry at 24 
hpi per group. (B-C) Epithelial cells (CD45-CD31-) were analyzed for tdTomato expression. 
(E) The percentage of infected (tdTomato+) ATI, ATII, and ATII cells was quantified. (B-E) 




Figure 3-6. Detection of epithelial cell types supporting primary transcription in vivo. (A) 
representative flow plots for identifying indicated cell types. (B) Total numbers of infected 
ATI, ATII, and ciliated cells following ∆PB1-Cre or ∆HA-Cre infection. (C) tdTomato gMFI 
of individual cell types compared to total tdTomato+ cells in ∆PB1-Cre and ∆HA-Cre 
infected mice. Data representative of 3 independent experiments with n=3-4 mice per 
group. Student’s t test (B) or one-way ANOVA with Dunnett’s multiple comparisons test 




Analysis of individual epithelial cell types in vivo 
We sorted out tdTomato+ and tdTomato- ATI, ATII, and ciliated cells from 
∆HA-Cre and ∆PB1-Cre infected Cre-inducible reporter mice for mRNA 
sequencing to characterize cell type- and stage-specific responses to scIAV 
infection. Cells from naïve mice were used as baseline controls. We and others 
have previously used CD24 as a marker of ciliated cells (158, 165), and we further 
validated its use by quantifying co-expression of CD24 with the ciliated cell marker 
acetylated alpha-tubulin (aat). Importantly, the majority of CD24hi cells also 
express aat, while CD24- cells do not express any aat (Figure 3-8A, Figure 3-7). 
We also validated our gating strategy by quantifying cell type-specific gene 
expression; we identified cell type-specific expression of both transcription factors 
and cell surface proteins associated with each cell type (Figure 3-8B) (166-168). 
Expression of innate immune signaling genes in naïve cells could contribute to any 
differences in the response between cell types. We therefore quantified expression 
of such genes in each cell type in naïve animals. ATI cells express higher basal 
Ddx58 (RIG-I) and Ifih1 (MDA5) than ATII cells or ciliated cells; other signaling 
genes—Irf3, Irf7, and Mavs—are not different between the cell types (Figure 3-
8C). Overall, these data confirm enrichment of the indicated epithelial cell types to 
analyze innate immune responses to scIAVs.   
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Figure 3-7. Verification of ciliated cell identity in vivo. Mice were infected with 105 PFU 
∆HA-mCherry and lungs harvested at 24 hpi for analysis by flow cytometry. 
Representative flow plots from infected (top) and fluorescence minus one control (bottom) 




Figure 3-8. Analysis of individual epithelial cell types in vivo. (A) B6 mice were infected 
with 105 PFU ∆HA-mCherry and lungs harvested at 24 hpi for analysis by flow cytometry. 
The percentage of CD24hi and CD24- cells that are aat+ was quantified. Data 
representative of one independent experiment with n=3 mice. (B-C) Lungs from naïve 
mice were harvested and ATI, ATII, and ciliated cells were FACS sorted for mRNA-seq 
analysis. Levels of the indicated cell type-specific (B) and innate immune signaling (C) 
genes were quantified. Data representative of one independent experiment with n=3 mice. 
One-way ANOVA with Tukey’s multiple comparisons test *** p<0.001, ** p<0.01, ns= not 
significant. 
 
Cell type-specific responses to stages of virus replication in vivo.  
To assess cell type-specific responses to infection, we first looked at global 
changes in host transcripts. ATI cells respond only to direct infection, with similar 
responses to primary transcription and amplified replication (Figure 3-9A, left). In 
contrast, ATII cells have a tiered response to direct infection, and uninfected ATII 
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cells from ∆HA-Cre infected mice are able to respond to global inflammation 
(Figure 3-9A, middle). Ciliated cells only respond to direct infection, and this 
response is tiered to different stages of virus replication (Figure 3-9A, right). 
Quantification of IAV gene expression—excluding HA and PB1 reads—in each cell 
type revealed no differences between ∆HA-Cre-infected cells, while ∆PB1-Cre-
infected ciliated cells have higher IAV reads than ∆PB1 infected ATI or ATII cells 
(Figure 3-9B). ATI, ATII, and ciliated cells all upregulate Ifnb in response to ∆HA-
Cre infection (Figure 3-10). In contrast to the in vitro data (Figure 3-4), ∆PB1-Cre 
is unable to induce detectable Ifnb in the analyzed cell types in vivo, which may be 
due to lower relative MOI. Importantly, these cell types also do not upregulate the 
IFN-dependent ISG Mx1 in response to ∆PB1-Cre infection, indicating that IFN is 
likely not secreted by any cell type. Both infected and uninfected cells upregulate 
Mx1 in response to ∆HA-Cre, suggesting that amplified virus replication is required 
to induce IFN production in vivo and any genes upregulated in ∆PB1-Cre infected 
cells, including genes designated as ISGs, are likely due to direct infection.   
We then analyzed the ISGs upregulated by primary transcription or 
amplified replication. We identified ISGs that were specific to ∆HA-Cre or ∆PB1-
Cre infection, as well as genes upregulated by both infections (Figure 3-9C, Table 
3-4). The previously identified putative protective ISGs (Figure 3-1E) are all 
upregulated exclusively by ∆HA-Cre infection. This could indicate that induction of 
a strongly antiviral response is dependent on de novo vRNA production and/or 
upregulation of IFN. We also identified genes that are only significantly upregulated 
in ∆PB1-infected cells. These genes may be upregulated in response to virus 
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entry, early trafficking of vRNPs, or some other early stage of virus infection. 
Following detection of virus RNAs, the genes upregulated in response to RLR 
signaling may dominate the transcriptome, which is why we do not see significant 
upregulation of these ∆PB1-specific genes in ∆HA infected mice.  
We compared ISGs upregulated in ∆HA-Cre infected IAV+ cells between 
cell types to identify cell type-specific responses to infection (Figure 3-9D, Table 
3-5). All cell types upregulate genes involved in antigen processing and 
presentation (Herc6, Psmb8, Rnf213, Tap1). Ciliated cells were the only cells to 
upregulate several genes involved in endocytosis and vesicle transport (Amph, 
Msr1). ATI and ATII cells specifically upregulated RNA metabolism-associated 
genes (Cnp, Isg20, Pnpt1), which may be employed as a way to target and 
degrade virus RNAs. In response to ∆HA-Cre infection, all cell types were able to 
upregulate the putative protective ISG Helz2 (Figure 3-1E, Table 3-1). However, 
only ATII cells upregulated Adar, Eif2ak2, and Pml, which all have known anti-IAV 
activity (27, 132, 169). While all cell types upregulate Stat1 and the positive RLR 
regulator Ddx60, only ATII and ciliated cells upregulate Ddx58 (RIG-I), Ifih1 
(MDA5), and Stat2. These data suggest that different cell types may employ 
unique strategies that are compatible with the cell function to make the cell 
inhospitable to virus replication. 
We were also able to compare ISGs upregulated in IAV+ or IAV- cells over 
naïve cells as a way to identify infection-specific ISGs (Figure 3-9E, Table 3-6). 
Many innate signaling genes are upregulated in both infected and uninfected cells 
from ∆HA-Cre infected mice (RLRs, Irf7, Tlr3). Among the infection-specific ISGs 
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upregulated during ∆HA-Cre infection are genes associated with apoptosis (Ripk2, 
Casp1, Ifi27, Pmaip1) and E3 ubiquitin ligases and proteasome genes, some of 
which are known to be involved in MHC-I antigen processing (Neurl3, Rnf19b, 
Psmb9). While many known ISGs with anti-IAV activity are upregulated in both 
IAV+ and IAV- cells, Eif2ak2 is infection-specific. Repair of virus-induced DNA 
damage is critical for cell survival from IAV infection (170), and several DNA 
damage response-associated genes (Bub1, Ddit4, Pml) were found to be infection-
specific. Overall, the cell type infected, the stage of IAV replication, and direct 














Figure 3-9. Cell type-specific responses to stages of virus replication in vivo. Cre reporter 
mice were infected with 105 pfu ∆HA-Cre or ∆PB1-Cre and tdTomato+ and tdTomato- ATI, 
ATII, and ciliated cells were sorted at 24 hpi for mRNA-seq analysis. (A) MDS plots of the 
indicated cell type. (B) IAV CPM in tdTomato+ cells infected with the indicated virus. (C) 
Unique and overlapping ISGs significantly upregulated (logFC≥1.5, FDR ≤0.05, CPM≥10 
in at least one population) in ∆HA- or ∆PB1-infected tdTomato+ cells compared to naïve 
indicated cell type. (D) Unique and overlapping ISGs significantly upregulated in ∆HA-
infected tdTomato+ cells. (E) Infection-specific ISGs were identified by comparing genes 
in tdTomato+ (∆HA/∆PB1+) and tdTomato- (∆HA/PB1-) mice. Data representative of one 






Figure 3-10. Amplified scIAV replication is required for IFN signaling. Expression of Ifnb 
(top) and Mx1 (bottom) in ATI, ATII, and ciliated cells in the indicated condition. Data 



































Atf3 Maff Arg2 Nrn1 Abtb2 Mafb Steap4 Abca9 Junb Abca9 Ifit1bl1
Ceacam1 Marcksl1 Ceacam1 Pi4k2b Adar Maff Adm Lamp3 Atp10d Ifit2
Cebpd Mov10 Fut4 Psmb8 Atf3 Mx1 Ahnak2 Lgals9 Ccna1 Ifit3
Cnp Mx1 Gk Psmb9 B4galt5 Mx2 Amph Lmo2 Ceacam1 Ifitm3
Cxcl10 Mx2 Lamp3 Rab27a Bst2 Neurl3 Apol6 Lrg1 Cebpd Irf7
Ddit4 Nfil3 Lrg1 Sqle Ccl5 Nt5c3 Arg2 Map3k14 Ddx60 Lamp3
Ddx60 Oas3 Mthfd2l Steap4 Cd274 Parp12 Atf3 Marcksl1 Fam46c Lgals9
Dhx58 Psmb8 Cdkn1a Pfkfb3 Atp10d Mastl Gpx2 Slfn5
Fut4 Rgs1 Ceacam1 Pml Batf2 Mb21d1 Herc6 Steap4
Gch1 Rnf213 Csrnp1 Pnpt1 Bcl3 Msr1 Hk2
Gem Rsad2 Cxcl10 Psmb8 Bst2 Mx1
Gk Rtp4 Ddx58 Ripk2 Bub1 Mx2
Gpx2 Stat2 Ddx60 Rnf19b Casp1 Neurl3
Helz2 Steap4 Dhx58 Rnf213 Cd38 Nod2
Herc6 Tap1 Dtx3l Rsad2 Ceacam1 Oas2
Ifi44 Tlr3 Eif2ak2 Rtp4 Cebpd Oas3
Ifit1 Tnfaip3 Epsti1 Serpine1 Cxcl10 Pim3
Irf7 Tnfsf10 Gbp2 Slc1a1 Cxcl11 Pmaip1
Isg15 Trim14 Gbp3 Sp110 Cyp1b1 Psmb8
Isg20 Usp18 Gbp5 Spats2l Ddx58 Psmb9
Lap3 Vmp1 Gch1 Stat1 Ddx60 Rgs1
Lgals9 Xaf1 Helz2 Stat2 Dtx3l Rnf213
Lrg1 Zbp1 Herc6 Steap4 Dusp5 Rsad2
Ifi27l2a Tap1 Epsti1 Samhd1
Ifi35 Tlr3 Fam46c Sat1
Ifi44 Tnfaip3 Flt1 Serpinb9
Ifih1 Tnfsf10 Gbp2 Serpine1
Ifit1 Trafd1 Gbp3 Slc15a3
Ifit2 Trim21 Gbp5 Slc16a1
Ifit3 Uba7 Gem Slc25a30
Ifitm3 Ube2l6 Gja5 Slfn5
Irf7 Usp18 Helz2 Stat1
Irf9 Xaf1 Herc6 Stat2
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Atf3 Maff Abtb2 Mafb Abca9 Junb
Ceacam1 Marcksl1 Adar Maff Adm Lamp3
Cebpd Mov10 Atf3 Mx1 Ahnak2 Lgals9
Cnp Mx1 B4galt5 Mx2 Amph Lmo2
Cxcl10 Mx2 Bst2 Neurl3 Apol6 Lrg1
Ddit4 Nfil3 Ccl5 Nt5c3 Arg2 Map3k14
Ddx60 Oas3 Cd274 Parp12 Atf3 Marcksl1
Dhx58 Psmb8 Cdkn1a Pfkfb3 Atp10d Mastl
Fut4 Rgs1 Ceacam1 Pml Batf2 Mb21d1
Gch1 Rnf213 Csrnp1 Pnpt1 Bcl3 Msr1
Gem Rsad2 Cxcl10 Psmb8 Bst2 Mx1
Gk Rtp4 Ddx58 Ripk2 Bub1 Mx2
Gpx2 Stat2 Ddx60 Rnf19b Casp1 Neurl3
Helz2 Steap4 Dhx58 Rnf213 Cd38 Nod2
Herc6 Tap1 Dtx3l Rsad2 Ceacam1 Oas2
Ifi44 Tlr3 Eif2ak2 Rtp4 Cebpd Oas3
Ifit1 Tnfaip3 Epsti1 Serpine1 Cxcl10 Pim3
Irf7 Tnfsf10 Gbp2 Slc1a1 Cxcl11 Pmaip1
Isg15 Trim14 Gbp3 Sp110 Cyp1b1 Psmb8
Isg20 Usp18 Gbp5 Spats2l Ddx58 Psmb9
Lap3 Vmp1 Gch1 Stat1 Ddx60 Rgs1
Lgals9 Xaf1 Helz2 Stat2 Dtx3l Rnf213
Lrg1 Zbp1 Herc6 Steap4 Dusp5 Rsad2
Ifi27l2a Tap1 Epsti1 Samhd1
Ifi35 Tlr3 Fam46c Sat1
Ifi44 Tnfaip3 Flt1 Serpinb9
Ifih1 Tnfsf10 Gbp2 Serpine1
Ifit1 Trafd1 Gbp3 Slc15a3
Ifit2 Trim21 Gbp5 Slc16a1
Ifit3 Uba7 Gem Slc25a30
Ifitm3 Ube2l6 Gja5 Slfn5
Irf7 Usp18 Helz2 Stat1
Irf9 Xaf1 Herc6 Stat2














ATI cells ATII cells Ciliated cells
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Abca9 Lamp3 Adar Lgals9 Arg2 Ifit3 Ddx60 Ifitm3
Abtb2 Lap3 Bst2 Mx1 Abca9 Ifitm3 Ifit1 Irf7
Adar Lgals9 Cxcl10 Mx2 Atp10d Irf7 Ifit3
Adm Lmo2 Ddx58 Oas2 Ccna1 Lamp3
Ahnak2 Lrg1 Ddx60 Oas3 Ceacam1 Lgals9
Amph Mafb Dhx58 Parp12 Cebpd Lrg1
Apol6 Maff Dtx3l Psmb8 Ddx60 Mthfd2l
Arg2 Map3k14 Epsti1 Rnf213 Fam46c Nrn1
Atf3 Marcksl1 Gbp2 Rsad2 Fut4 Pi4k2b
Atp10d Mastl Gbp3 Rtp4 Gk Psmb8
B4galt5 Mb21d1 Gbp5 Sp110 Gpx2 Psmb9
Batf2 Mov10 Helz2 Stat1 Herc6 Rab27a
Bcl3 Msr1 Herc6 Stat2 Hk2 Slfn5
Bst2 Mx1 Ifi27l2a Steap4 Ifit1bl1 Sqle
Bub1 Mx2 Ifi35 Tap1 Ifit2 Steap4
Casp1 Neurl3 Ifi44 Tlr3
Ccl5 Nfil3 Ifih1 Tnfsf10
Cd274 Nod2 Ifit1 Trafd1
Cd38 Nt5c3 Ifit1bl1 Uba7
Cdkn1a Oas2 Ifit2 Ube2l6
Ceacam1 Oas3 Ifit3 Usp18
Cebpd Parp12 Ifitm3 Xaf1
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DISCUSSION 
The early innate response in infected cells is critical for controlling IAV 
pathogenesis in vivo. Following import into the nucleus, the IAV RdRp first 
transcribes vRNA to generate mRNA and protein. After de novo polymerase 
complexes are generated, the vRNA is replicated. These two distinct stages of 
early virus replication are of critical importance in innate immune signaling, as de 
novo vRNA is necessary for induction of IFN-b during IAV infection. IFN-b 
production within the first hour of IAV infection has been documented in both 
human and mouse cells (171). IFN-independent, IRF-dependent upregulation of 
some ISGs has been described (31-33). In these studies, detection of viral RNA 
products is still required for virus-induced gene expression. We are unable to 
detect IFN expression following ∆PB1 infection in vivo, and the observed induction 
of antiviral genes could therefore be driven directly through RLR signaling. 
Membrane perturbations—such as those that occur during virus binding and entry 
into the host cell—have been shown to be sufficient to induce IRF3-mediated gene 
activation in vitro (35), and this response is independent of RLR signaling (34). The 
upregulation of ISGs we see during ∆PB1 infection could therefore be due to virus 
entry rather than production of new virus RNA species, and these responses would 
be revealed in RLR signaling deficient cells. As RIG-I knockout and MAVS 
knockout cells do not significantly upregulate any genes following ∆PB1-mCherry 
infection, virus entry induces little response in vitro. However, the ∆PB1-specific 
genes upregulated in vivo may be in response to entry. An additional facet of the 
early innate immune response to viruses is the upregulation of endogenous 
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transposable elements (172). This upregulation occurs prior to IFN induction. As 
primary transcription is sufficient for induction of antiviral genes, transposable 
elements are likely also upregulated and contributing to the cellular response.  
Various techniques have been employed to assess distinct stages of IAV 
infection within a cell. These studies use inhibitors to prevent protein synthesis or 
transcription, which effectively halt virus replication but also target cellular 
processes (155-157). This limits the ability to analyze the immune response, as 
expression of host genes is compromised. Specific inhibition of virus replication 
could be achieved by using drugs that target the IAV polymerase specifically, either 
by targeted drug design or by engineering IAVs to be susceptible to drug control, 
as described through the use of the small molecule assisted shutoff tag. Addition 
of this tag to an IAV polymerase gene resulted in an IAV whose replication was 
susceptible to hepatitis C virus protease inhibitors (173), allowing for specific 
inhibition of IAV replication. In addition to inhibition of replication, recent studies 
using single-cell RNA sequencing technologies have uncovered cellular responses 
to IAVs lacking one or more gene segments, including viruses lacking polymerase 
segments. Similar to our results using ∆PB1 scIAVs, cells infected with viruses 
lacking vRNP genes produce less virus mRNA and induce little to no IFN (62). 
However, a virus lacking both PB1 and NS1 potently induced IFN (63). While our 
data suggest that primary transcription can induce antiviral gene expression in an 
IFN-independent manner, in the absence of immune antagonism, primary IAV 
transcription may be sufficient to drive IFN expression.  
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 We and others have identified cell type-specific responses to IAV infection 
in vivo (158, 165). Unlike previous studies, we are able to compare three different 
epithelial cell types, the stage of replication (primary virus transcription vs amplified 
replication), and assess the response of bystander cells. Some of these cell type 
differences may be explained by an incompatibility with certain ISGs and the 
function of a given cell type (e.g. expression of Eif2ak2 may be incompatible with 
critical ciliated cell function). The only ISG upregulated by all cell types in during 
both full replication and primary transcription is Steap4. STEAP4—also known as 
STAMP2—is a metalloreductase that has antiviral activity during hepatitis B virus 
(HBV) infection. STEAP4 prevents HBV-induced metabolic dysregulation and can 
antagonize HBV gene expression, thereby protecting cells from HBV (174). 
Expression of Steap4 in scIAV-infected cells could serve a similar function. 
Basal levels of signaling genes may contribute to the observed differential 
antiviral responses between cell types. However, this does not fully explain 
expression differences, as ATI cells express higher levels of Ddx58 and Ifih1 
(Figure 3-8C) but ciliated cells upregulate the most ISGs, even in uninfected cells. 
In addition to upregulating more ISGs than other epithelial cell types, the highest 
upregulated ISG in ∆PB1-Cre-infected ciliated cells is Ifitm3. IFITM3 is known to 
inhibit entry/uncoating of IAV (25, 26); the potent upregulation of Ifitm3 during early 
stages of infection and/or the rapid upregulation of ISGs could explain our 
previously described protection of ciliated cells during virus spread (158). The 
epigenetic landscape of different cell types prior to and during early infection could 
 88 
also contribute to differences in gene expression, as epigenetic differences affect 
functional outcomes during virus infections (175).  
RIG-I is known to detect short (10-300bp) cytosolic RNAs with 5’ 
triphosphate ends (176). While aberrant (-)-sense IAV RNA products—DI 
genomes and mini viral RNAs—are detected by RIG-I, the contribution of (+)-
sense IAV RNAs to innate immune detection is unclear. Triphosphate-independent 
recognition of lariat structures derived from vRNA and cRNA has been described, 
and both potently upregulate IFN-I (177). ∆PB1 viruses are able to generate (+)-
sense RNA, therefore cRNA-derived structures could be driving the response to 
∆PB1 infection.  
 Overall, we have described the use of a genetically restricted scIAV to 
assess cell type- and virus replication stage-specific host responses to infection. 
We determined that both primary virus transcription and amplified replication are 
detected through RIG-I. Additionally, we found that the magnitude of early 
replication, the stage of replication, and the cell type infected all contribute to the 
antiviral response in vivo. Altogether, these data offer insight into the mechanisms 
of innate immune activation during IAV infection.  
 
FOOTNOTES 




2Additional contributions: ∆PB1 viruses and ∆HA-Cre viruses were generated by 
S.L. Aron. Flow cytometry experiments were completed by E.J. Fay and S.L. Aron 
and analyzed by E.J. Fay. RNA-seq experiments were completed by E.J. Fay and 
S.L. Aron and analyzed by E.J. Fay, M.G. Macchietto, M.W. Markman, and S. 
Shen. K. Esser-Nobis and M. Gale, Jr. generated A549 KO cells. E.J. Fay and R.A. 
Langlois wrote the manuscript. 
 
3Abbreviations used this chapter: aat, acetylated alpha-tubulin; ATI, type I alveolar; 
ATII, type II alveolar; CPM, counts per million; Cre, Cre recombinase; cRNA, 
complementary RNA; DI, defective interfering; EpCAM, epithelial cell adhesion 
molecule; FACS, fluorescence-activated cell sorting; FDR, false discovery rate; 
GFP, green fluorescent protein; gMFI, geometric mean fluorescence intensity; GO, 
gene ontology; HA, hemagglutinin; HBV, hepatitis B virus; i.n., intranasal; IAV, 
influenza A virus; IFITM3, IFN-induced transmembrane protein 3; IFN, interferon; 
ISG, IFN-stimulated gene; logFC, logarithmic fold change; MAVS, mitochondrial 
antiviral signaling protein; MDA5, melanoma differentiation-associated protein 5; 
MDCK, Madin-Darby canine kidney; MDS, multidimensional scaling; MHC, major 
histocompatibility complex; NA, neuraminidase; NTC, non-targeting control; PB1, 
polymerase basic 1; PFU, plaque forming unit; PKR, protein kinase R; RdRp, RNA-
dependent RNA polymerase; RIG-I, retinoic acid-inducible gene 1; RLR, RIG-I-like 
receptor; scIAV, single-cycle IAV; STAMP2, six transmembrane protein of prostate 
2; STEAP4, six transmembrane epithelial antigen of the prostate 4; vRNA, viral 
RNA; vRNP, viral ribonucleoprotein  
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 Viruses emerging from zoonotic reservoirs represent a major public health 
concern. While identifying potential zoonoses is paramount to pandemic 
preparedness, there are few experimental models that are able to characterize 
virus and host factors necessary for cross-species transmission. Here, we 
leverage a model whereby pet store mice—which harbor a myriad of mouse 
pathogens—are co-housed with clean laboratory mice. This ‘dirty’ mouse model 
offers a platform for studying the acute transmission of viruses between hosts via 
natural mechanisms—through direct contact, air, and saliva and other fluids. We 
co-housed pet store mice with wild type laboratory mice and mice that are deficient 
in interferon receptors and harvested various organs for RNA sequencing analysis. 
This model system gives us unique access to both the reservoir and the new host, 
allowing us to analyze mutations and adaptations that occur in the virus population 
during transmission to and spread within a new host. We have also co-housed our 
laboratory mice with the bedding of pet store rats to analyze species-specific 
immune and non-immune barriers to transmission. By also analyzing the virus 
infections in the rats, we will be able to identify virus mutations necessary to 
overcome these species barriers. Overall, this mouse model allows for the analysis 





Many emerging viruses are transmitted to humans from zoonotic reservoirs. 
These viruses represent a major public health risk, as existing immunity to human 
viruses offer little protection against these viruses. Classic examples of zoonoses 
include human immunodeficiency virus (HIV), Ebolavirus, and avian influenza 
viruses (178-180). The ongoing outbreak of a novel coronavirus highlights the 
critical need for pandemic preparedness in the face of zoonotic viruses. 
Understanding virus adaptations that allow for transmission within and between 
animal species is imperative to understand mechanisms of emergence. 
 Viruses are capable of rapid evolution to both adapt to new hosts and evade 
host immune responses. Within a single host, a virus population will exist with a 
wide array of variants. Very few virus particles transmit between hosts, creating a 
genetic bottleneck (181). The subset of variants that do transmit rapidly expands 
to create a new variant population in the new host. The viral diversity within a host 
can have a dramatic impact on the outcome of infection and the potential for spread 
to additional hosts. 
There is little preexisting immunity to novel emerging viruses, making innate 
immune control of emerging viruses necessary for survival of the host and 
preventing spread to a new host. Innate immune responses—interferon (IFN) in 
particular—has placed immense evolutionary pressure on viruses, and this 
pressure continues on presently emerging viruses. Understanding how viruses 
evolve to evade innate immune pressures in a new host is a critical to 
understanding zoonotic transmission to humans. In the case of HIV-1, the 
 92 
precursor SIV first gained the ability to spread from monkeys to chimpanzees, then 
from chimpanzees to humans. A major driver of zoonotic transmission to humans 
was the adaptation of HIV-1 to antagonize the human restriction factors APOBEC3 
family proteins and Tetherin, highlighting the importance of immune evasion in 
permitting cross-species transmission events (178, 182). The ability to identify 
such adaptations in circulating virus populations in animal species may help predict 
viruses with potential to spread to humans, allowing us to better prepare for 
pandemics. 
Rodentia is the most diversified mammalian order, comprising 40% of all 
mammalian species (183). Rodents harbor many pathogens because they live in 
dense, highly social groups. Because of the close proximity to humans, many 
mouse pathogens have transmitted to humans, including lymphocytic 
choriomeningitis virus and Leptospira species (184). Rodent-borne hantaviruses 
are a global public health concern, as they can cause severe disease, including 
hemorrhagic fever, in humans despite limited pathology in rodent hosts (185). 
Additional pathogens have been identified in wild-caught mice and other rodents 
(184, 186, 187). Rodents—along with primates and bats—have historically been 
dominant reservoirs for pathogens that jump to humans, and it is pertinent to 
understand how viruses transmit within and between rodent species.  
We are using a model whereby pet store mice—which harbor a myriad of 
natural mouse pathogens—are co-housed with our specific pathogen free (SPF) 
laboratory mice. During co-housing, pathogens and other microbes transmit from 
the pet store mice to our laboratory mice, giving us the opportunity to assess 
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transmission of viruses via natural routes—through air, direct contact, feces, and 
saliva and other fluids (188). We have found a broad array of viruses and other 
pathogens in pet store mice, many of which are able to spread to co-housed mice. 
Several of these virus populations appear to be dynamic as they transmit to and 
disseminate within a new host. By using laboratory mice deficient in IFN signaling, 
we assessed the role of the IFN response in constraining virus populations during 
transmission and spread. Additionally, through the use of pet store rats, we have 
identified rat pathogens that are able to overcome species barriers and replicate 
in mice. Overall, the dirty mouse platform can be used to characterize barriers to 
virus transmission. 
 
MATERIALS AND METHODS 
Mice, co-housing, and antibiotic treatment. 
 Wild-type C57BL/6J and B6(Cg)-Ifnar1tm1.2Ees/J (IFNaR-/-) mice were 
purchased from The Jackson Laboratory. B6.IL-28RA−/− (IFNlR-/-) and B6.IL-
28RA-/-Ifnar1-/- (IFNalR-/-) mice were a kind gift from Dr. Sergio Kotenko (Rutgers 
University, (21, 189)). Pet store mice were purchased from Twin Cities area pet 
stores. Mice were co-housed within a BSL-3 facility. Age-matched mice housed in 
SPF facilities served as controls. 250 µL antibiotic cocktail (1 mg/mL ampicillin, 10 
mg/mL metronidazole, 5 mg/mL vancomycin, 10 mg/mL neomycin) or water was 





 Pet store mice were screened using EZ-spot methods (Charles River 
Laboratories). Whole blood was collected at the time of sacrifice and submitted as 
per the Charles River Laboratories guidelines.  
 
Identification of viral species by mRNA-seq 
Indicated tissues were homogenized in a GentleMacs M tube (Miltenyi 
Biotec) in Buffer RLT Plus (Qiagen) supplemented with 2-mercaptoethanol (10 
µL/1 mL) and Reagent DX (0.5% v/v, Qiagen). RNA was extracted using the 
AllPrep DNA/RNA Mini kit (Qiagen). TruSeq mRNA Stranded cDNA libraries were 
sequenced using NovaSeq (Illumina, 50bp PE reads). 12-20 million reads/sample 
were obtained. Total reads were mapped to the Mus musculus genome (mm10) 
and unmapped reads were extracted using STAR aligner (191). Unmapped reads 
were concatenated an assembled using Trinity (192). Prospective species IDs 
were assigned to each assembled contig using BLASTn. The estimated counts for 
each species was calculated using Salmon (193). Normalized virus reads were 
generated using DESeq2 (194).  
 
Phylogenetic analysis 
 Reads mapping to the narnavirus-like RdRp were assembled and 
translated. Similar protein sequences were identified using NCBI BLASTp and 
were used to construct the phylogenetic tree. Alignments between these 
sequences and the novel sequence were built using Clustal Omega (195). 
 95 




Total reads were mapped to the Mus musculus genome (mm10) and 
unmapped reads were extracted using STAR aligner, concatenated, and 
assembled using Trinity as described above. Assembled contigs were aligned to 
the indicated viral gene for per-contig variant analysis using BLASTn. Viral 
genomes used were murine astrovirus 2 (GenBank: MF175073.1) and murine 
hepatitis virus A59 (GenBank: MF618252.1).  
 
Amplicon sequencing and variant analysis 
Amplicon sequencing will be performed based on previously described 
methods (197). Briefly, primers for the murine astrovirus RNA-dependent RNA 
polymerase (RdRp) and capsid genes, the MHV spike glycoprotein gene, and the 
kobuvirus capsid gene were designed based on sequences identified in tissue 
samples from pet store and co-housed mice. Previously described primers were 
used to amplify pan-kobuvirus 3D gene (RdRp) (198), pan-coronavirus RdRp 
(199), and lymphocytic choriomeningitis virus S gene (184) (see Table 4-1 for 
primer information). Primers were designed to amplify 200-600bp regions of the 
gene of interest. Virus amplicons were generated using the SuperScript IV One-
Step RT-PCR System (ThermoFisher Scientific). Amplicons were isolated by gel 
electrophoresis and purified using the NucleoSpin Gel and PCR Clean-up kit 
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(Macherey-Nagel). Paired-end 250nt reads will be generated using the MiSeq v2 
platform (Illumina). Each amplicon will be independently generated and sequenced 
in duplicate. 
 




Care and use of the animals was in accordance with the Guide for the Care 
and Use of Laboratory Animals from the National Research Council and the USDA 
Animal Care Resource Guide. All experimental protocols involving the use of mice 
were approved by the Institutional Animal Care and Use Committee at the 






































Identifying pathogens that transmit from pet store mice to co-housed 
laboratory mice 
Virus emergence from zoonotic reservoirs can cause devastating 
pandemics and remains a global threat to human populations. To understand how 
viruses evolve as they spread within rodent species, we have leveraged a 
previously described model whereby pet store mice (Mus musculus) are co-
housed with specific pathogen free (SPF) laboratory mice (188). During co-house, 
pathogens will transmit from the pet store mice to the SPF mice, allowing us to 
assess virus populations both within the reservoir (pet store mice) and the recipient 
(SPF mice). Wild-type B6 (B6), IFN-a receptor knockout (IFNaR-/-), IFN-l receptor 
knockout (IFNlR-/-), and double receptor knockout (IFNalR-/-) mice were co-
housed with pet store mice for up to 5 days, at which time animals were sacrificed 
and indicated tissues were processed for mRNA-seq analysis. This cage set-up 
was repeated three independent times. Additional co-house cages with only some 
SPF mouse strains and pet store mice from a single pet store were also analyzed; 
analyses will only include these cages when noted. During co-house, IFN knockout 
animals typically lose weight (Figure 4-1). Upon sacrifice, one pet store mouse in 
cage 1 was found to have an intestinal blockage, which would affect fecal-oral 
transmission of pathogens and may explain the lack of weight loss. Cage 3 SPF 
mice—particularly the IFNalR-/- mouse—were moribund at day 3 post co-house 
and were therefore sacrificed for analysis at that time. 
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 We co-housed SPF mice with mice from two different pet stores to increase 
pathogen diversity in the model. Mice from these pet stores have distinct pathogen 
histories as revealed by serology (Figure 4-2A). For example, only mice from pet 
store B have been exposed to pneumonia virus of mice. To identify viruses that 
are transmitting and replicating, we created cDNA libraries using polyadenylated 
(polyA) RNA. We developed a pipeline to extract non-mouse reads from the total 
RNA, assemble these into contigs, and search for sequence similarity to published 
data (Figure4-2B). Using this approach, we identified many pathogens in the pet 
store mice—including viruses—and some of these pathogens transmit to the co-
housed mice (Figure 4-2C).  
While a polyA-based cDNA synthesis approach was selected to specifically 
identify viruses transmitting and replicating in our mice, this will exclude viruses 
that do not polyadenylate their mRNAs. Such viruses include arenaviruses and 
hantaviruses. Specifically, this approach will exclude lymphocytic choriomeningitis 
virus (LCMV), which has been identified in pet store mice by serology and can 
transmit to co-housed SPF mice (188). We therefore screened our pet store mice 
for LCMV by PCR using primers for the LCMV S gene. We identified one pet store 
mouse positive for LCMV (Figure 4-2D). Additional PCR screening will determine 
if LCMV has transmitted to co-housed SPF mice.  
While many viruses readily transmit from pet store mice to co-housed SPF 
mice, several viruses have been identified in pet store mice that never transmit. 
Feline stool-associated (FESA)-like virus reads have been identified in pet store 
small intestine and spleen/lymph node samples (Figure 4-2C). FESA-like virus 
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may be present in other animals in the pet store and have the ability to transmit to 
but not between mice, making mice a dead-end host for the virus. Lactate 
dehydrogenase-elevating virus (LDV)—which is known to transmit vertically in 
mice (200)—does not transmit to co-housed mice (Figure 4-3A). This verifies our 
model is working biologically and bioinformatically and suggests minimal cross-
contamination between samples. Many viruses that do transmit to co-housed mice 
transmit readily to all strains of SPF mice. However, murine norovirus (MNV) 
transmits more robustly to IFN receptor knockout strains, particularly IFNalR-/- 
mice (Figure 4-3B). Altogether, these data show the dirty mouse model can be 
used to characterize transmission of viruses.  
 
 
Figure 4-1. Co-housed SPF mice lose weight. B6, IFNaR-/-, IFNlR-/-, and IFNalR-/- mice 
were co-housed with pet store mice for up to 5 days. Pet store mice were purchased on 
day 0. Three individual cages were set up in three consecutive weeks using new pet store 





Figure 4-2. Identification of pathogens in pet store and co-housed SPF mice. (A) Serum 
from mice from pet store A and pet store B was tested for antibodies against the indicated 
pathogens. Columns are individual mice. (B) Pipeline for identifying pathogen reads from 
total polyadenylated RNA sequencing data. (C) Summary of pathogens identified in pet 
store mice (left) and in co-housed mice (right) that do not appear in non-co-housed SPF 
mice. Colored circles indicate tissue. Includes cages with only some SPF strains. (D) 






Figure 4-3. Viruses with unique transmission patterns. Pooled spleen/lymph node (A) or 
small intestine (B) RNA was sequenced as in figure 4-2. (A) Normalized reads mapping 
to lactate dehydrogenase-elevating virus in the indicated mouse. (B) Normalized reads 
mapping to murine norovirus in the indicated mouse. Dotted line connects mice from the 
same co-housed cage.  
 
Co-transmission analysis identifies a novel alveolate virus 
In addition to identifying viruses, we identified several other parasites 
present in the intestines of pet store mice that transmitted to co-housed mice. We 
were able to assess co-transmission of pathogens (Figure 4-4A). This identified a 
strong correlation between Cryptosporidium spp. and a set of viral reads similar to 
Wilkie narna-like and Matryoshka RNA viruses (Figure 4-4B). Matryoshka viruses 
were identified in Plasmodium and Leucocytozoon species and were so named 
because they are viruses that infect a parasite that infects an animal, analogous 
to the Russian nesting dolls (201). Similarly, Wilkie narna-like virus (WNLV) was 
identified in mosquitos but likely infects fungi that infect mosquitos (202). 
Protozoan Cryptosporidium are obligate gastrointestinal parasites that can cause 
gastroenteritis in many vertebrate species including humans, particularly among 
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immunocompromised hosts (203, 204). The reads identified in our samples 
mapped to the WNLV RdRp, and phylogenetic analysis suggests a novel 
narnavirus (Figure 4-4C). This novel virus likely infects Cryptosporidium within our 
mice. Ongoing analyses will explore additional transmission correlations.  
 
Figure 4-4. Co-transmission analysis identifies a novel alveolate virus. (A) Transmission 
correlation heat map. Includes cages with only some SPF strains. (B) Correlation as in (A) 
for reads mapping to Cryptosporidium species and WNLV. (C) Reads mapping to WNLV 
virus RdRp were assembled and translated. Similar proteins were identified using NCBI 
BLASTp and were used to build a maximum likelihood phylogenetic tree. The scale bar 










































































































































































































































































































































































































































































































































































































































Amplicon-based approach to quantify virus variants  
 While we identified many murine viruses transmitting from pet store mice to 
SPF mice, we selected three viruses for variant analysis. Murine astrovirus-2 
(MAst-2) was identified in all three cages and readily transmitted to co-housed 
mice (Figure 4-5A). In cages where it was present, murine hepatitis virus (MHV) 
was the most abundant virus in the mice, accounting for up to 7% of total reads in 
some small intestine samples (Figure 4-6A, bottom). Reads mapping to murine 
kobuvirus (MKobu) were much lower. However, using pan-kobuvirus primers 
specific for the conserved RdRP, we were able to amplify kobuvirus RNA from 
samples with very low MKobu read counts in the deep sequencing data (Table 4-
2).  
We performed preliminary variant analysis for reads mapping to MAst-2 
because we achieved near-complete sequence coverage in many of our tissue 
samples (Figure 4-5B). We specifically analyzed contigs mapping to the virus 
RdRp and the capsid. We found little derivation from the published sequence for 
reads mapping to the RdRP, and the variant per 100 base pairs does not increase 
following transmission or dissemination (Figure 4-5C, left). The number of variants 
per 100 base pairs is much higher in reads mapping to the capsid sequence, and 
we overall see more contigs with greater variance following transmission and 
dissemination (Figure 4-5C, right). These data suggest that the capsid region of 
the MASt-2 genome is more plastic than the RdRP, and that there may be changes 
in the virus population during transmission and dissemination. While we obtained 
lower coverage of the MHV genome in some samples (Figure 4-6B), we were able 
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to perform variant analysis on the MHV RdRp and the surface spike glycoprotein. 
Similar to MAst-2, contigs mapping to the spike gene contain more variants per 
100 base pairs than contigs mapping to the RdRp (Figure 4-6C).  
Using mRNA-seq, we were able to identify reads mapping to known viruses. 
However, we did not achieve sufficient depth to quantify virus variants and 
bottlenecks during transmission and dissemination. Additionally, variability in gene 
sequences between samples could be due to sequencing error rather than 
biological variance, and technical replicates are needed to verify results. We 
therefore designed primers to amplify 200-600 bp regions of the RdRp and the 
spike glycoprotein (MHV) or capsid (MAst-2 and MKobu) gene for each virus. 
Amplicons will be generated in duplicate and deep sequenced with a minimum of 
400 reads per site, as described previously (197). The consensus sequence of the 
amplified region in the pet store small intestine (SI), co-housed SI, and co-housed 
liver will be determined and compared between animals within a single cage. 
Additionally, variant analysis will be performed to identify bottlenecks and/or 
adaptive changes that occurred during transmission (pet store SI to co-housed SI) 
and dissemination (co-housed SI to co-house liver). Variants will be called at a 3% 
frequency minimum across replicates. Analyses will be performed using the iVar 




Figure 4-5. Murine astrovirus-2 readily transmits to and disseminates in co-housed mice. 
(A) Normalized reads mapping to the MAst-2 genome in the indicated tissue in the 
indicated mouse. (B) Coverage of MAst-2 genome in a single cage. (C) Reads mapping 
to the MAst-2 RdRp (left; contig length 255-1551 nt) or capsid (right; contig length 202-
2500 nt) in the indicated tissues of mice in a single cage were analyzed for similarity to 
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Figure 4-6. Murine hepatitis virus readily transmits to and disseminates in co-housed 
mice. (A) Normalized reads mapping to the MHV genome in the indicated tissue in the 
indicated mouse. (B) Coverage of MHV genome in a single cage. (C) Reads mapping to 
the MHV RdRp (left; contig length 204-18,142 nt) or spike glycoprotein (right; contig length 
253-2353 nt) in the indicated tissues of mice in a single cage were analyzed for similarity 
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Table 4-2. Kobuvirus identified by RT-PCR. + or – denotes positive or negative screen 





Identifying species barriers to transmission using rat fomites 
 In order to infect and replicate within a new species, a virus needs to both 
evade the new host immune system and use key host proteins for replication, such 
as entry and protein synthesis machinery. To extend the use of our model system 
to include identification of these immune and non-immune species barriers to 
cross-species transmission, we obtained two rats (Rattus norvegicus) from 
different pet stores and co-housed them together. We transferred bedding—
including fecal matter—daily from rat cages to cages of our SPF B6 and IFNalR-
/- mice for 7 days (Figure 4-7A-B). Additionally, we homogenized fresh fecal pellets 
from each rat in PBS and delivered 200µL to each mouse via oral gavage daily. 
After 7 days, we sacrificed both the rats and the mice for deep sequencing of the 
SI and liver. We also transferred bedding and delivered oral gavage to a cage of 
Mouse Tissue 3D (RdRp) amplicon MKobu mRNA-seq reads
B6-cohoused SI + 0
IFNAR KO-cohoused SI + 222
IFNLR KO-cohoused SI + 1115
IFNLAR KO-cohoused SI + 280
Pet A SI + 22
Pet B SI + 9
B6-cohoused SI + 63
IFNAR KO-cohoused SI +/- 11
IFNLR KO-cohoused SI + 5
IFNLAR KO-cohoused SI + 75
Pet A SI - 15
Pet B SI + 3
B6-cohoused SI - 0
IFNAR KO-cohoused SI - 5
IFNLR KO-cohoused SI - 28
IFNLAR KO-cohoused SI - 8
Pet B SI + 63
Pet A SI - 21
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SPF IFNalR-/- mice for 5 days, then transferred the mice to a new cage and added 
SPF B6 mice (Figure 4-7C-D). After an additional 7 days, we sacrificed mice for 
deep sequencing the SI and liver. In this model, any pathogen from the rats first 
needs to overcome non-immune species barriers to replicate in the IFNalR-/- mice 
and would then need to adapt immune evasion strategies to replicate in the B6 
mice. Sequencing and analysis are ongoing, however SPF mice lost weight during 
bedding transfer (Figure 4-7B/D). Overall, this model will allow us to identify 
patterns of virus adaptations that allow for cross-species transmission. 
 
 
Figure 4-7. Pet store rats to characterize cross-species transmission of pathogens. (A) 
Bedding from the pet store rat cage was transferred to cages of SPF B6 or IFNalR-/- mice 
daily for 7 days. After 7 days, rats and mice were sacrificed for virome analysis. (B) Weight 
loss of mice in (A). (C) Bedding from the pet store rat cage was transferred to a cage of 
IFNalR-/- mice daily for 5 days. After 5 days, the IFNalR-/- mice were moved to a fresh 
cage with SPF B6 mice. After an additional 7 days, mice were sacrificed for virome 
analysis. (D) weight loss of mice in (C).  
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ONGOING ANALYSES AND FUTURE DIRECTIONS 
 In addition to amplicon sequencing and analysis of cross-species 
transmission using pet store rats, we are also performing 16s sequencing on small 
and large intestine contents for all experiments. These data will add depth to our 
co-transmission analysis. Bacteria are known to stabilize some picornaviruses, 
and the intestinal microbiota enhances infection of an array of enteric viruses (205-
207). To further examine the relationship between bacterial and viral transmission, 
we co-housed SPF B6 and IFNaR-/- mice with pet store mice that have been given 
antibiotics via oral gavage (Figure 4-8A). After 5 days, we sacrificed mice for 
virome sequencing. While we saw more robust MAst-2 transmission to IFNaR-/- 
mice from antibiotic-treated pet store mice (Figure 4-8B), we are currently 
validating depletion of intestinal bacteria in our pet store mice. We will perform 
additional replicates and include all strains of SPF mice to validate these results. 
In addition to analyzing bacterial reads in intestinal contents, we will also sequence 
the total RNA in the intestinal contents. This will identify viruses and other 
pathogens that transmit to co-housed mice but are unable to infect/replicate in the 
new host. This will be especially critical for cross-species experiments, as it could 





Figure 4-8. Antibiotic treatment to analyze the role of intestinal bacteria in virus 
transmission. (A) Model and timeline for antibiotic treatment. (B) Normalized reads 
mapping to MAst-2 in the small intestine of indicated mice from cages with control (left) or 
antibiotic treated (right) pet store mice. Dotted lines connect mice from individual cages.  
 
DISCUSSION 
Zoonotic pathogens are a serious public health concern. Understanding the 
adaptive changes that allow for species jump into humans is paramount to 
predicting and responding to emerging viruses. A key step to identifying viruses 
that have the potential to transmit to humans is comprehensive virome profiling of 
species that live in close contact with humans, including rodent species. Another 
approach to analyze pathogen transmission is to through ‘rewilded’ laboratory 
mice, or mice released into semi-secure outdoor environments (208, 209). While 
pathogens do transmit to the mice, there have not been robust virus infections in 
this model. Additionally, in these models, only the current host of the virus is 
known; it is not known where these pathogens originated or what changes 
occurred to allow them to replicate in mice. In our experimental system, we 
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uniquely have access to both the original reservoir and the new host. Through 
available knockout mice, we are also able to analyze the critical role of innate 
immune proteins in transmission and spread in a new host. This model can be 
extended to characterize the role of additional proteins such as pattern recognition 
receptors that detect virus infections and key signaling proteins that amplify the 
response. Additionally, we can use different hosts as sources for pathogens, 
including using other species of rodents. The species used in the model system 
described here—Mus musculus and Rattus norvegicus—are estimated to have 
diverged 10-12 million years ago (mya) (210, 211). We may see differences in 
pathogen transmission when the host is more (e.g. deer mice, Peromyscus 
maniculatus, ~25 mya (210)) or less (e.g. Mus subgenus Nannomys, ~7 mya 
(212)) diverged. Wild-caught mice show similar immune activation compared to 
pet store mice (188), but potentially have been exposed to unique pathogens. Co-
housing laboratory mice with wild mice would therefore expand our system to 
include additional murine pathogens.  
 While our model is currently limited to rodent pathogens, the virus families 
we identified have human species that are significant public health concerns. 
Human astroviruses have only recently been appreciated as a leading cause of 
viral gastroenteritis worldwide. Astrovirus strains have been identified in many 
species, and there is evidence of interspecies transmission (213). MHV is the 
longstanding model of coronavirus infections and has produced much of our 
knowledge of basic coronavirus biology (214). Aichi virus—human kobuvirus—
infections cause gastroenteritis, nausea, and fever, and 80-95% of adults 
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worldwide have antibodies against Aichi virus (198). Severe disease and death 
can occur in young children, particularly in developing countries (215). Many 
picornaviruses are well-studied, however the unique capsid structure of 
kobuviruses could result in distinct mechanisms of virus entry and genome release 
(216, 217). Kobuviruses have been identified in many animal species, and cross-
species transmission likely exists (198, 215). There is no animal model, and 
isolation and characterization of a murine kobuvirus will offer important insight into 
kobuvirus pathogenesis. 
Here, we describe the dirty mouse model as a platform for analyzing 
transmission of pathogens within and between species. We have identified 
pathogens that readily transmit from pet store mice to co-housed laboratory mice. 
Through amplicon sequencing, we will identify changes in populations of virus 
species that occur during transmission and dissemination and the role of IFN 
during these processes. Additionally, using pet store rats, we will identify and 
characterize cross-species transmission events. This model can be expanded to 
analyze the role of additional host factors in transmission. Overall, this 
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associated; HIV, human immunodeficiency virus; IFN, interferon; IFNaR, IFN-a 
receptor; IFNlR, IFN-l receptor; LCMV, lymphocytic choriomeningitis virus; LDV, 
lactate dehydrogenase elevating virus; LIV, liver; MAst-2, murine astrovirus 2; 
MHV, murine hepatitis virus; MKobu, murine kobuvirus; MNV, murine norovirus; 
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 Predicting which viruses have pandemic potential in humans is extremely 
difficult. It requires both extensive screening of animal populations to track viromes 
and an in-depth understanding of virus and host factors that allow a virus to 
replicate in a given host. My thesis work has—to some degree—addressed both 
of these concerns. In Chapters 2 and 3, I described studies that have elucidated 
mechanisms of resistance or susceptibility to influenza infection using single-cycle 
influenza A viruses (scIAVs). This work revealed distinct antiviral signatures 
associated with the magnitude of scIAV replication, the stage of replication, and 
the cell type infected in a mouse model. In Chapter 4, I introduced a new model 
for assessing intra- and inter-species barriers to virus transmission. This model 
provides a platform for identifying and characterizing innate immune barriers to 
virus transmission. Here, I discuss the broad implications of my thesis work.  
 
Replication and response heterogeneity during early IAV infection 
 Replication heterogeneity observed during early IAV infection is likely due 
to both virus and host factors and is both a cause and effect of the antiviral 
response heterogeneity. The ability to identify cells that are resistant to IAV 
infection could reveal novel IAV restriction factors. Helz2 was consistently 
upregulated in cells with low IAV infection (Figure 3-1E) but has no defined antiviral 
activity against IAV. Additionally, we found that cells with high levels of IAV 
 115 
replication upregulate inflammatory cytokines and upregulate apoptosis-associate 
genes as early as 12 hpi (Figures 2-5G and 3-1E). These data suggest that only a 
subset of infected cells contribute to severe immunopathology. Further defining 
virus and host factors that contribute to this phenotype could reveal novel 
therapeutic targets to treat severe IAV infections.  
With the advancement of deep sequencing technologies—particularly the 
development of single-cell sequencing—many groups have identified 
heterogeneity in the antiviral response within an infected cell population. This is at 
least partially a result of heterogeneity in a virus population; for example, during 
IAV infection, cells infected with viruses lacking the immune antagonist gene NS1 
were the primary inducers of interferon (IFN) (63). Similarly, both magnitude of IAV 
replication and the abundance of defective viral genomes contribute to the immune 
response in vitro (161). Virus differences do not always account for immune 
differences, as was found during West Nile virus infection (64). Using a 
combination of chromatin immunoprecipitation with sequencing (ChIP-seq), bulk 
RNA-seq, and single cell RNA-seq (scRNA-seq), it was found that innate immune 
genes such as cytokines and chemokines that display high cell-to-cell variability in 
their expression are also genes that are highly divergent across species (218). In 
contrast, regulatory genes are both more conserved evolutionarily and less 
variable between responding cells in a population. These data suggest that 
immune response heterogeneity will always be observed between cells during 
infection, independent of viral factors. 
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Cell type-specific innate immune responses to IAV 
 The epithelial cell types analyzed in Chapters 2 and 3 all have critical 
functions in the lung: type I alveolar (ATI) cells are the site of gas exchange (167), 
type II alveolar (ATII) cells secrete surfactant to maintain pulmonary compliance 
(167), and ciliated cells produce mucus and help expel pathogens from the lung 
(219). The differential immune responses we uncovered between these cell types 
are likely both a cause and effect of their functions. Basal differences in the cell 
biology likely contribute to differential ability to respond, and the responses may 
have evolved to maintain the important functions of each cell type during IAV 
infection.   
 We uncovered basal differential expression of immune signaling genes 
between ATI, ATII, and ciliated cells (Figure 3-8C). However, this only partially 
explains differences in the response to scIAVs. The efficiency of entry and early 
trafficking to the nucleus could affect the early replication and resulting response. 
This could be why ciliated cells display higher levels of IAV mRNA following ∆PB1 
infection (Figure 3-9B) and more robust IFN-stimulated gene (ISG) activation 
following infection with either scIAV (Figure 3-9C). IAV relies on the microtubule 
network for intracellular trafficking, and IAV entry requires reorganization of the 
cytoskeletal network (220). Ciliary beating—the mechanism by which ciliated cells 
expel pathogens—requires careful organization of microtubule architecture (221). 
This results in a unique cytoskeletal network compared to other epithelial cell 
types, and this difference may drive in early differences in scIAV entry, trafficking, 
and replication in ciliated cells.  
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The rapid induction of ISGs in ciliated cells could also explain their unique 
protection against ‘secondary’ infection (i.e. virus spread; Figure 2-7), particularly 
because of the upregulation of Ifitm3. IFITM3 inhibits early stages of IAV infection, 
including entry and uncoating (25, 26). Ciliated cells may be poised to respond to 
IFN stimulation and rapidly upregulate potent antiviral genes as a way to preserve 
mucociliary clearance during infection. Epigenetic modifications are known to 
modulate the immune response to virus infections (175). Differences in the 
epigenetic landscape of naïve epithelial cell types could lead to differential 
accessibility for virus-activated transcription factors and ultimately differences in 
gene expression during early infection.  
 Some cell type-specific ISGs upregulated during ∆HA-Cre infection regulate 
or perform metabolic functions (e.g. ATI: Ddit4, Fut4; ATII: B4gal5, Pfkfb3; ciliated 
cells: Cyp1b1, Hk2; Table 3-5). Signaling through IFN receptors can activate 
kinases other than classical JAKs, including PI3K (222). A major target of PI3K is 
mTOR, a master regulator of cell metabolism, growth, and survival (223). PI3K 
activation has been described during IAV infection, both as a result of binding/entry 
and via IAV NS1 (224). Activation of PI3K during IAV infection could have many 
functional outcomes due to the varied outputs of PI3K activity between cell types, 
either due to expression or activation differences for PI3K and its signaling 
partners. Differences in naïve cell metabolic states could result in IFN-dependent, 
JAK-independent differential gene expression.  
 Some components of the IFN response can be toxic to cells. OAS family 
proteins—which sense and initiate degradation of dsRNA through RNase L—can 
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sense and induce destruction of cellular RNAs (93, 225). PKR activity inhibits 
protein synthesis and can induce cell death during virus infection (226, 227). For 
this reason, IFN signaling and antiviral gene activity are tightly regulated. While the 
evolutionary loss of some innate immune genes has been described between 
species, there could also be evolutionary mechanisms to prevent expression of 
certain genes in a cell type-specific manner within an organism. PKR, OAS2, and 
OAS3 are all upregulated by ∆HA-Cre in a cell type-specific manner (ATII only, 
ciliated cells only, and ATI and ciliated cells, respectively, Table 3-5). Different cell 
types may be more susceptible to the deleterious effects of these or other antiviral 
proteins, leading to mechanisms of repression. Stem cells do not respond to IFN, 
and this is at least partially due to inaccessible ISREs (72, 74, 228). Similar 
restrictions could limit antiviral gene expression in a cell type-specific manner.  
  
Virus adaptations during transmission and dissemination 
While huge numbers of virions can be produced within an infected host, 
relatively few transmit/disseminate to a new site of infection (181). This creates a 
genetic bottleneck where the genetic diversity within the original reservoir is 
reduced to few variants in the new host. Such bottlenecks could be viewed as 
evolutionarily disadvantageous, as random transmission would bypass natural 
selection. However, some variants may be poised for more efficient 
dissemination/transmission, and this would remove deleterious mutations from the 
population in the new site of infection. The presence of certain traits within a virus 
population, such as the ability to induce IFN production, can have a profound 
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impact on the rest of the virus population and could ultimately affect spread (229). 
The experimental system described in Chapter 4 could help identify variant 
patterns associated with transmission and dissemination, as well as the 
susceptibility of such variants to IFN.  
For viruses that can replicate in more than one tissue, adaptations may be 
necessary for dissemination. Measles virus first replicates in lymphatic tissues then 
spreads to epithelial tissues; this dissemination is associated with adaptations in 
the virus phosphoprotein and changes in virus gene expression levels, primarily 
expression of an IFN antagonist protein (230). For many viruses broadened tissue 
tropism is associated with more severe disease, including during IAV infections 
(231, 232). Characterizing virus adaptations that allow for dissemination within a 
host can help identify factors associated with severe pathogenesis. Additionally, 
the efficacy of antiviral drugs may vary depending on tissue tropism; identifying 
tissue-specific virus adaptations could identify novel therapeutic targets for severe 
virus infections.  
Many predictions of viruses with pandemic potential rely on computational 
analyses applied to empirical data. Such analyses must take into account both 
virus and host traits that could impact spread. While many factors contribute to IAV 
zoonosis, there are several host factors that establish species specificity of IAV, 
including surface sialic acids and the nuclear protein ANP32A (233). Similarly, 
there are known variants in IAV genes that allow for spread between avian and 
mammalian hosts (233). These patterns of adaptations that contribute to zoonosis 
likely exist for other viruses and could be identified through comprehensive 
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profiling of viromes within different species. It is important to not just predict which 
viruses can jump to humans, but also which viruses could cause severe pathology 
in humans. Using data on known human viruses, virus family and primary tissue 
tropism are the strongest predictors of virulence (234). Furthermore, higher 
disease mortality is associated with greater evolutionary distance between hosts 
(235). The expansion of the model described in Chapter 4 to include additional 
hosts could reveal additional factors that contribute to pathogenesis. Additional 
factors, such as global distribution and virus richness within a species, can also 
impact zoonotic potential (236). There are many complex interacting factors that 
permit or prohibit zoonosis, and a deeper understanding of any of these 
mechanisms will aid in pandemic predictions and preparedness. Ultimately, 
understanding both the virus and host factors that contribute to cross-species 
transmission will improve our ability to identify viruses in zoonotic reservoirs that 
could spread to humans. 
 
FOOTNOTES 
1Abbreviations used this chapter: ANP32A, acidic nuclear phosphoprotein 32 
family member A; ATI, type I alveolar; ATII, type II alveolar; IAV, influenza A virus; 
IFITM3, IFN-induced transmembrane protein 3; IFN, interferon; ISG, IFN-
stimulated gene; ISRE, IFN-stimulated response element; JAK, Janus kinase; 
mTOR, mammalian target of rapamycin; NS1, nonstructural 1; OAS, 
oligoadenylate synthetase; PB1, polymerase basic 1; PI3K, phosphoinositide 3-
kinase; PKR, protein kinase R; scIAV, single-cycle IAV 
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